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Abstract  
 
 Cancer constitutes a terrible burden on modern society.  In the United States 
there are an estimated 1,658,370 new cancer diagnoses resulting in 589,430 deaths in 
2015 alone.[1]  An estimated 41,170 of these cases will be diagnosed right here in 
Virginia.  With new cancer patients comes the expanding demand for new treatments.  
As we all know, many modern chemotherapeutics cause adverse reactions to patients.  
This is because the toxic nature of these therapies often affects normal tissue alongside 
the tumors that are infesting the body.  Therefore, researching novel ways to make 
chemotherapeutics selective for cancer, while leaving healthy tissue unscathed, is of 
paramount importance.  There are a few ways in which we have approached cancer-
specific chemotherapeutics.  Through the use of light controlled toxicity and drug 
release and the targeting of tumor phenotypes such as overexpressed proteins and the 
Warburg effect, we begin to tackle the problem of non-specificity of current 
chemotherapeutics. 
 Combretastatin A-4 (CA4) is highly potent anticancer drug that acts as an 
inhibitor of tubulin polymerization.[2, 3] The core of the CA4 structure contains a cis-
stilbene, and it is known that the trans isomer is significantly less potent. We prepared 
an azobenzene analog of CA4 (Azo-CA4) that shows 13-35 fold enhancement in 
potency upon external irradiation. GI50 values in the light were in the mid nM range.  
Due to its ability to thermally revert to the less toxic trans form, Azo-CA4 also has the 
ability to automatically turn its activity off with time.  Therefore, this work establishes a 
novel strategy for switchable potency for cancer treatment. 
x 
 
 
 
 Doxorubicin (Adriamycin) is an anthracycline type of chemotherapeutic that 
intercalates double-stranded DNA.[4]  Although this drug has played a huge role in the 
treatment of cancer, its usefulness declines in cases of cancer recurrence because of 
the impact this drug has on the cardiovascular system.  Therefore, we prepared this 
drug as a cell impermeable conjugate that gains penetrability through the use of 
external radiation.[5] 
 Folate receptor alpha (FRα) is overexpressed in a variety of cancer cells and 
accepts folic acid as a natural ligand.[6]  Therefore, conjugation of drugs to folic acid 
introduces a promising way to bring these drugs to cancer cells with greater specificity.  
We took this concept one step further with the introduction of a photo-labile linker, 
connecting doxorubicin to folic acid, which offers dual-specificity through ligand 
targeting and light activation. 
 Finally, many cancer cells produce adenosine triphosphate, the energy currency 
of a cell, through an abnormal upregulation of glycolysis.[7]  This pathway results in a 
larger-than-normal production of lactic acid and lowers the pH of cancer cells through a 
phenomenon known as the Warburg Effect.  We hypothesized that through the use of L-
canavanine, an L-arginine analog, we could construct short peptides that would gain cell 
permeability in a low pH environment.  Attaching a cargo to these peptides, such as 
doxorubicin will ultimately allow for targeting the low pH extracellular environment of 
cancer cells.   Through the use of these strategies we have furthered the fight 
against cancer.  Targeting cancer by taking advantage of its phenotypes or through the 
use of light is vital in reducing negative side-effects of current chemotherapeutics.  The 
xi 
 
 
 
novel technologies offered above bring us a step closer to side-effect free treatment of 
cancer patients.  
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CHAPTER 1. INTRODUCTION 
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1.1 Cancer and Chemotherapy 
 Cancer remains one of the most dreaded diagnoses that a patient may receive.  
According to the American Cancer Society, cancer will affect one half of men and one 
third of women during their lifetimes.  In 2015 there will be an estimated 1.7 million 
cancer diagnoses resulting in almost 600,000 deaths in the United States alone.[1]  
Thus, new treatments for cancer are in demand.  Treatments for cancer have evolved 
over the years.  Common treatments include surgery, radiation therapy, and 
chemotherapy. 
 Cancer chemotherapy began in the 1940’s with the use of nitrogen mustards, 
which are DNA alkylating agents.  Not long after this was the discovery of the anticancer 
properties of aminopterin,[8] a folic acid analog, which was later replaced by a similar, 
but more effective drug, methotrexate.[9]  These discoveries ushered in an era of 
targeting cancer using chemotherapeutics. 
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1.1.1 Classes of Chemotherapeutics 
  Many types of cancer chemotherapeutics exist today.  Among these 
include alkylating agents[10] such as the aforementioned nitrogen mustards.  These 
agents work by alkylating guanine, damaging DNA, and ultimately preventing DNA 
replication, which is necessary for cell division and proliferation.   Others inhibit the 
interaction of topoisomerase I & II with DNA[11] including irinotecan and topotecan.  
Topoisomerase inhibitors gain their lethality by blocking the ligation step of DNA coiling, 
which leads to diminished integrity of the genome and apoptosis.  Similar to the 
topisomerase inhibitors are anthracyclines such as doxorubicin[12] which intercalates 
into double stranded DNA and prevents the progression of topoisomerase II.  In the 
presence of doxorubicin, topoisomerase II is unable to re-seal double stranded DNA 
after the initial breakage of the base pairs.  There is also a class of cancer drugs known 
as mitotic inhibitors that target a variety of proteins associated with mitosis[13].  Mitotic 
inhibitors generally gain effectiveness from inhibiting microtubule formation, which is 
involved in cell splitting.  During my thesis work, I focused primarily on two of these 
drugs, doxorubicin, which is in an anthracycline class and combretastatin A-4, which 
falls into the mitotic inhibitor class.  
 
1.1.2 Doxorubicin and Combretastatin A-4 
Doxorubicin 
  Doxorubicin (Dox), also known as Adriamycin, bears close structural 
resemblance to the more abundant natural product daunomycin (Figure 1.1).  
Daunomycin,  also known as daunorubicin, is produced by Streptomyces peucetius, a 
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species of bacterium.  Dox is used in treating a variety of cancers including leukemia, 
breast, bone, lung and brain cancers and has several known mechanisms of action that 
result in cell death.[4]  Dox is widely known as a DNA intercalator, but can be toxic in 
other ways.  Dox is also known to bind to topoisomerases I and II preventing their 
dissociation from DNA and leading to DNA damage through double strand breaks.[14] 
Dox also stabilizes topoisomerase II and inhibits the enzyme from dissociating from 
DNA which leads to breaks which trigger an apoptotic pathway.  Furthermore, stress on 
the genome of a cell can cause over activation of poly(ADP-ribose) polymerase-1 
(PARP-1), depleting energy reserves and resulting in cell death.[15]  
 
 
 
 
 
Figure 1.1.  Structures of doxorubicin (left) and daunomycin (right). 
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Combretastatin A-4 
 Combretastatin A-4 (CA4) and its water soluble phosphate prodrug CA4P 
(fosbretabulin) are a class of chemotherapeutics known as mitotic inhibitors.  CA4 is 
known to bind at the colchicine binding site of β-tubulin, and is inhibitory at micromolar 
levels (IC50 = 1.9 ± 0.2 μM).
[16]  CA4 prevents heterodimer polymerization with α-tubulin 
in vitro.   Destabilization of tubulin polymerization inside cells leads to cell cycle arrest 
and prevents mitosis, ultimately leading to activation of apoptosis via caspase-9 and 
PARP cleavage or through mitotic catastrophe.[17]  CA4P is currently in clinical trials 
against a variety of cancer types with different combinations of chemotherapeutics.[18, 
19][20]  For example,  CA4P has been used in conjunction with carboplatin and paclitaxel 
to treat platinum resistant ovarian cancer.[21]   
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1.2 Targeting Cancer 
 Off-target toxicity persists as a challenge with chemotherapeutics.  A promising 
avenue towards treating cancer involves finding what makes cancer cells unique from 
healthy cells and how we might target these anomalies.  There are a few ways to 
identify possible cancer-specific molecular targets.  One way is to look at the relative 
abundance of certain proteins in a cancer cell compared to a healthy cell.  For example, 
HER2, a cell surface epidermal growth factor receptor, is overexpressed in aggressive 
forms of breast cancer and has been targeted by chemotherapeutic agents.[22]  A 
comparable example, folate receptor α (FRα), is overexpressed in epithelial ovarian 
tumors at a level 10- to 100-fold higher than normal expression.[23]  This presents an 
intriguing target for chemotherapeutics.  One application of targeting FRα comes in the 
imaging of tumors.  Gallium 67–chelator complexes have been fused to folic acid to 
enhance the selectivity of radio-imaging tumors.[24]  Many examples of folate targeted 
therapeutics are found in the literature.[25]  Folic acid has been conjugated to protein 
toxins to inhibit protein synthesis,[26] attached to chemotherapeutics,[27] used for 
immunotherapies,[28] and conjugated to liposomes[29] and nanoparticles.[30] 
 Another way to target cancer is to see if mutations in cancer cells result in 
modified protein function, which ultimately increases proliferative phenotypes.  p53, 
which normally acts as a tumor suppressing protein, is known to be mutated in many 
types of cancer.[31]  p53 can activate DNA repair proteins to repair damaged DNA, arrest 
cell growth allowing for time for DNA repair, and initiate apoptosis.  If one or all of these 
functions of p53 is altered by a mutation, the result may be a proliferating cell that is 
unable to regulate DNA repair or initiate cell death.  These are some of the main 
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ingredients in the recipe for cancer.  As a result, drugs that target p53 mutants and 
downstream pathways have been developed.[32] 
 Lastly, genetic alterations of genes that normally code for two different proteins 
can join and create fusion-proteins  Many fusion-proteins, such as modified tyrosine 
kinase ROS1, have been shown to drive cellular proliferation.[33]  Inhibiting the function 
of this fusion-protein through use of a small molecule ligand may be a viable approach 
to targeting cancers expressing this phenotype.  For example, Gleevec, also known as 
Imantinib, is a small molecule inhibitor of BCR-Abl tyrosine kinase that is found 
exclusively in cancer cells.[34] 
 In targeting these characteristics of cancer cells we begin to tackle the issue of 
off-target toxicity through enhancing specificity. 
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1.3 Light Targeted Chemotherapeutics 
 Another interesting approach toward the specificity of chemotherapeutics comes 
through the use of light.  There are a variety of ways that light has been used to 
specifically target cancer cells, but all focus on the idea that a drug or process that is 
detrimental to a cancer cell will only be activated where irradiated.  Perhaps the most 
common form of light targeted cancer treatment comes with a technique known as 
photodynamic therapy (PDT). 
 
1.3.1 Photodynamic therapy 
  Photodynamic therapy (PDT) utilizes a photosensitizer to create reactive 
oxygen species (ROS) which are toxic to cells (Figure 1.2).  Initially, hematoporphyrin, a 
photosensitizer, was found to fluoresce under ultraviolet light irradiation.[35]  In the 
1970’s hematoporphyrin was used to treat animal tumors as it was found to be 
preferentially retained in cancer tissue.[36]  Since the first clinical trials around this time, 
a myriad of photosensitizers have been introduced.  Some examples of photosensitizers 
include porfimer (Photofrin®), and Photogem® (Figure 1.3).  They work by taking light 
energy and converting it to ROS through a photosynthetic process that involves the 
oxygen in the environment of the targeted tissue.[37]  Therefore, three pieces are needed 
for PDT; light, photosensitizers, and oxygen.  As the field of PDT has grown, so too 
have the photosensitizers and methods for delivering light.  Because longer wavelength 
light passes more easily through tissue, photosensitizers that are sensitive to near-IR 
light, such as lutetium texaphyrin, have emerged.[38] 
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Figure 1.2.  Pathway of creating reactive oxygen species through the use of 
photosensitizers. 
 
 
 
Figure 1.3.  Structures of clinically approved photosensitizers are shown above 
exhibiting similar porphyrin backbones. 
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1.3.2 Limitations of PDT 
  Photodynamic therapy (PDT) is an attractive way of targeting localized 
tumors because of its noninvasive nature.  However, PDT has several drawbacks in 
clinical uses.  One of the drawbacks is the requirement of an oxygen rich environment 
to be effective;  yet tumors are often hypoxic.[39]  In addition to this drawback, many 
photosensitizers, such as Photofrin®, absorb light in the 630 – 690 nm range.[40]  These 
wavelengths can be absorbed by some of the chromophores found in tissue, such as 
melanin.[41]  To measure treatment effectiveness, researchers define penetration depth 
of light as the depth where incident light intensity decreases to 37% because of 
scattering.[42]  At 630nm, a wavelength relevant to Photofrin®, 37% of incident light is 
achieved after only 3-5mm.  In addition, scattering of light in the tissue results in lower 
intensity light and a change in the direction of the light beam.  A final drawback of PDT 
comes from administration of the photosensitizers.  Photosensitizers must be allowed to 
achieve high enough concentrations at the tumor site before irradiation can occur.[43]  It 
can be difficult to determine the best irradiation time as different patients metabolize 
photosensitizers at different rates.  Also, sensitivity to ambient light can become an 
issue in the weeks and months following treatment. 
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1.4 Targeting the Acidic Environment of Cancer 
 Cancer cells, in general, exhibit a lower pH, both intracellularly and 
extracellularly, when compared to normal cells.  Through a process known as the 
Warburg Effect, cancer cells use utilize glycolysis to produce adenosine triphosphate 
(ATP), the energy currency of the cell.[7]  This aerobic glycolysis results in the 
production of lactic acid which results in the low pH environment of cancer cells. 
Much of the research targeting the acidic phenotype thus far has focused on pH 
sensitive polymers or micelles that break up and release drugs in a lower pH 
environment.[44, 45]  Early pH sensitive liposomes were constructed in part with a weakly 
acidic amphiphile which offers stability to a bilayer phase at neutral pH, but become 
protonated under acidic conditions, which ultimately destabilizes the liposome.  An 
exception to these delivery methods is the pH low insertion peptide (pHLIP).[46]  pHLIP 
is a water soluble peptide at physiological pH.  However, under acidic 
microenvironments the C-terminus of pHLIP forms an alpha-helix and inserts itself in to 
the lipid bilayers.[47]  However, drug delivery with pHLIP is limited as the peptide stays in 
the lipid bilayer.   
The hydrophobicity of the cellular membrane has evolved to protect the cell from 
exogenous biomolecules.  However, certain peptides, similar to pHLIP, are able to 
overcome this obstacle.  Cell penetrating peptides (CPP’s) were originally designed 
around the HIV TAT translocating factor and Antennapedia transcription factor.[48, 49]  
These peptides have been refined to include only the residues that are responsible for 
cell permeability, which are largely positively charged and arginine containing.  In 
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chapter 3, we investigate the possibility of pH sensitive versions of CPPs for pH 
sensitive delivery. 
 
1.5 Dual Targeting Chemotherapeutics 
 One way to increase specificity for cancer is through the method of dual 
targeting.  The idea of dual targeting introduces a concept of attacking cancer from two 
different angles to decrease off-target toxicity.  Many of the methods for dual targeting 
have centered on targeting an oncogenic pathway, targeting an overexpressed protein 
or receptor, or a combination of the two.  For example, folic acid has been conjugated to 
micelles containing doxorubicin.[50]  Doxorubicin preferentially targets cancer cells and 
by loading cancer-specific, folic acid coated micelles with Dox, dual targeting becomes 
realized.  Nanoparticles are easily functionalized and present good scaffold for dual-
targeting.  For example, Folic acid decorated nanoparticles containing moieties to 
release Dox in a low pH environment have been developed.[51] 
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CHAPTER 2. Photoswitchable Anticancer Activity via trans-cis Isomerization of a 
Combretastatin A-4 Analog 
 
 
 
 
 
 
 
 
I would like to acknowledge Charles E. Lyons and John C. Hackett for their contribution. 
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2.1 Introduction 
 Off-target toxicity persists as a challenge in the development and improvement of 
cancer chemotherapeutics.     The use of light is one means to target therapy at the 
tumor site.  In photodynamic therapy (PDT), a photosensitizer is employed to create 
cytotoxic reactive oxygen species (ROS) at a point of irradiation.[52, 53]  One of the 
clinical challenges involving PDT is that hypoxic tumor microenvironments can limit the 
ability to create sufficient ROS for therapy.[54, 55]  As an alternative, researchers have 
used light to trigger drug activation or drug delivery.  Examples include the release of 
anti-cancer drugs from a negatively charged, cell-impermeable small molecule along 
with release from cancer-targeting dendrimers, nanoparticles and liposomes.[5, 56-63]  
Although these methods for targeted drug delivery are promising, in all cases the drug 
activation is irreversible upon illumination.  Very recently, Presa and coworkers have 
developed Pt(II) complexes with ligands that can be switched between more toxic and 
less toxic forms depending on the wavelength of light used.[64]  One potential problem 
for the clinical application of each of these light-activated drug systems is that the 
activated drug can diffuse away from the illuminated site of the tumor, causing 
unwanted damage to the tissues it encounters.  An ideal light-activated drug would 
automatically revert to a less potent form over time in order to limit this off-target toxicity. 
 
2.2 Combretastatin A-4 
 Combretastatin A-4 was first extracted from Combretum Caffrum, an African 
Bushwillow tree, and shown to inhibit tubulin polymerization in 1989.[65]  CA4 (Figure 
2.1) is an anticancer drug that exhibits selective cytotoxicity toward tumor 
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vasculature.[66, 67]  A variety of cancer cells are highly sensitive to CA4 treatment. GI50 
values are often under 10 nM.[68, 69]  A prodrug of CA4 (CA4-phosphate) is currently 
being tested in clinical trials in combination with existing chemotherapy agents.[70, 71]   
CA4 contains a cis-stilbene structure (Figure 2.1), which is known to be 60-fold more 
potent than the trans isomer.[72]  We reasoned, therefore, that an analog of CA4 that 
could reversibly switch from the trans to the cis form with light would have novel 
photoactivatable properties.  Although stilbenes themselves are photoswitchable, this 
process requires <300 nm UV light which is toxic to cells.[73] 
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Figure 2.1. a) Design of Azo-CA4, a photoswitchable analog of CA4.  b) RI-MP2/def2-
TZVP derived[80] electronic structure of CA4 (left) and Azo-CA4 (right).  Labeled charges 
for non-hydrogen atoms were computed using the natural population analysis method.  
Computational experiments were performed by John C. Hackett.   
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2.3 Photoswitches and Azobenzene 
 Azobenzene, a molecule that undergoes trans-cis isomerization under irradiation, 
has a growing number of applications in polymer chemistry,[74] peptide secondary 
structure,[75] and for controlling drug activation.[76] 
 
2.4 Combretastatin A-4 on an Azobenzene Scaffold 
 Azobenzenes contain a molecular backbone that resembles the stilbenoid 
backbone of CA4, with the olefinic carbon atoms replaced with nitrogens (Figure 2.1).  
Yet, unlike stilbenes, azobenzenes are able to be switched from the trans to cis form 
with low intensity light that is compatible with cells.[77]  Moreover, when irradiation is 
terminated, the cis form of azobenzenes relaxes back to the thermodynamically stable 
trans form with a half-life that ranges from milliseconds to hours.[76, 78, 79]  In principle, 
therefore, an azobenzene analog of CA4 (Azo-CA4, Figure 1a) will exhibit the dual 
properties we desired: enhancement in potency with light and automatic turn-off over 
time. 
 To verify that our Azo-CA4 was, indeed, highly similar in structure to CA4, we 
performed a computational study (Figure 2.1).  Both molecules were fully optimized at 
the RI-MP2/def2-TZVP level of theory and natural population analyses were 
performed.[80] The optimized geometries are quite similar and the natural charges 
calculated for non-hydrogen atoms are almost identical with the exception of the 
nitrogens on the azo bridge. 
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2.5 Retrosynthetic Analysis of Azo-CA4 
 To build a combretastatin analog on an azobenzene scaffold, we decided to work 
on the two aryl substituents separately.  In searching the literature, we found a one-step 
synthesis of asymmetric azobenzenes and discovered the starting materials for this 
synthesis, 3,4,5-trimethoxyaniline and 2-methoxy-4-nitrophenol, were commercially 
available. 
 
2.6 Failed Synthetic Routes 
 2.6.1 Route 1 
 For our first attempt we tried a one-step synthesis between the nitrophenol and 
the Trimethoxyaniline (Scheme 2.2).[81]  However, no reaction occurred.  The proposed 
mechanism of this reaction is shown (Scheme 2.3). 
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Scheme 2.1:  Synthesis of Azo-CA4.  
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Scheme 2.2.  Shown are the failed synthetic schemes for route 1 and route 2. 
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2.6.2.   Route 2 
After the failed reaction the first thing that was tried was a microwave assisted 
synthesis.  Similar results were obtained.  The literature[81] that we were studying at the 
time showed poor yields when starting materials were extremely electron-rich, 
specifically on the nitroaromatic compound.  This is consistent with the proposed 
mechanism (Scheme 2.3) which begins with nucleophilic attack on the aromatic nitro 
group.  “Electron rich,” refers to the substituents on the rings besides the nitro moiety.  
We thought that under the current reaction conditions the phenolic moiety would be 
deprotonated, making the nitroaromatic compound extremely electron rich.  We, 
therefore, decided to use a silyl protecting group (TBDMS-Cl) to protect the phenolic 
moiety of the nitroaromatic compound that we could later remove with a fluorine anion 
(Scheme 2.2).  After protection of the phenolic moiety, the coupling step was carried out 
under similar conditions.  No product formation was observed. 
We hypothesized that making the nitro aniline more reactive might be an option 
moving forward.  We attempted to convert the amine of trimethoxyaniline to a nitroso 
group to be reacted with the other half of our molecule.  However, reaction of 
trimethoxyaniline with diphenyl diselenide did not yield nitroso compound.  We 
hypothesize that the nitroso compound was too reactive to be isolated. 
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2.7 Synthesis of Azo-CA4 
To synthesize Azo-CA4 (Scheme 2.1), we first protected the phenolic oxygen of 
nitroaniline 1 with a TBDMS group to give 2.2.  Compound 2.2 was coupled to 3,4,5-
trimethoxyaniline  with diacetoxyiodobenzene[82] to yield azobenzene 2.3 which was 
separable from homo-aniline coupling side products.  Finally, 2.3 was deprotected with 
fluoride ion to yield Azo-CA4, 2.4.  
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Scheme 2.3.  The proposed mechanism of an asymmetric azobenzene formation 
between nitrophenol and aniline in the presence of strong base.[81] 
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2.8 Kinetics of Photoswitching and thermal relaxation 
 The first step in assessing Azo-CA4 was to analyze the kinetics of 
photoswitching.  We analyzed the photoswitching properties of Azo-CA4 (Figure 2.2).  
The absorbance spectrum of trans azo-CA4 showed a λmax of 379 nm and an 
extinction coefficient that is in accordance with other electron-rich trans azobenzenes 
(Figures 2.2a, 2.3, and 2.4).[83]  After 30 seconds of irradiation with 380 nm light, the 
compound’s absorption pattern had dramatically shifted toward an absorption profile 
that is characteristic for cis azobenzenes[84, 85] (Figure 2.2a).  Over time Azo-CA4 
reverted back to the trans form with a half-life of 84 min at 37°C (Figure 2.2b and c, and 
2.4).  Multiple cycles of switching and relaxation could be performed over 24 h without 
degradation (Figure 2.2d). 
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Figure 2.2. Determination of the molar absorptivity of Azo-CA-4 on a NanoDrop 
spectrophotometer with a 0.1 cm pathlength.  
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Figure 2.3. Absorption experiments performed on Azo-CA4. a) Absorption spectra of Azo-
CA4 (157 μM) after exposure to 380 nm light (4.4 mW/cm2) for various amounts of time.  b) 
Absorption spectra demonstrating thermal relaxation over time of Azo-CA4 in the dark at 
37°C.  Prior to placing in the dark, Azo-CA4 was treated for 1 minute with 380 nm light 
(4.4mW/cm2).  c) Time course of Azo-CA4 relaxation monitored by absorbance at 380 nm. d) 
Time course of 380 nm absorbance of Azo-CA4 over time.  The sample was irradiated with 
380nm light (4.4mW/cm2) for 1 minute every 3 hours at 37°C (arrows).  The final point 
indicates a fully dark-adapted Azo-CA4 left in the dark for 100 hours after the last irradiation. 
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Figure 2.4. Exponential decay of absorbance of Azo-CA4 at 380nm.  Azo-CA4 was 
irradiated with 380nm light for 1 minute.  Absorbance readings were taken every 60 
seconds for ~3hr and subtracted from the initial absorbance reading.  
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2.9 Tubulin polymerization assays 
 The first big test in the possible use of Azo-CA4 as a cancer drug was to test its 
ability to inhibit tubulin polymerization in vitro.  We then sought to demonstrate that Azo-
CA4 would inhibit tubulin polymerization in a similar manner to CA4 (Figure 2.5 and 
2.6).  In vitro experiments were carried out in the light using a fluorescent tubulin 
polymerization assay.  We sought to show that Azo-CA4 was a more potent inhibitor of 
tubulin polymerization when irradiated with light.  We compared our findings with the 
same experiments done with a negative vehicle control and combretastatin A4 (Figure 
2.6)   As expected, in the light, Azo-CA4 was a more potent inhibitor of tubulin 
polymerization than in the dark; light activated Azo-CA4 had an IC50 of 5.1 μM (Figure 
2.6), similar to the IC50 of CA4 (1.9 μM).
[2]   
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Figure 2.5.  In-vitro tubulin polymerization inhibition assay. Tubulin fluorescence 
was monitored every minute for 1 hour.  Closed circles represent tubulin 
containing wells irradiated with light (4.4 mW/cm2) for 1 min in the presence Azo-
CA4 prior to the start of the assay.  Open triangles represent tubulin exposed to 
Azo-CA4 without illumination. 
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Figure 2.6. Tubulin polymerization represented as fluorescence of a binder of tubulin 
heterodimer (Cytoskeleton, Inc, CO, USA).  Vehicle control (6.2% DMSO in H2O, closed 
triangles), Azo-CA4 in the absence of light (20μM, closed circles), Azo-CA4 irradiated 
with 4.4mW/cm2 light at 380nm immediately prior to the experiment (20μM, open 
circles), and CA4 (20μM, open triangles).  Experiments were performed in triplicate in a 
BioTek Synergy H1 Hybrid plate reader.  
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2.10 Cell viability assays 
 To investigate if the trend in tubulin polymerization inhibition would translate to 
potency in living cells, we performed cell viability assays on human umbilical vein 
endothelial cells (HUVEC), as CA4 is known to be especially potent towards tumor 
vasculature.[86][87]  We also evaluated the effects of Azo-CA4 on a breast 
adenocarcinoma epithelial cell line (MDA-MB-231) that has shown sensitivity to CA4[88] 
and was used as a model for cancer.  Assays with CA4 itself in these cell lines showed 
the expected growth inhibitory profile and a GI50 in the low nM range, consistent with 
other reports (Figure 2.7).[3] With Azo-CA4, we observed significant enhancement of 
growth inhibition in the presence of light vs. untreated controls for both cell lines (Figure 
2.8).  In HUVEC cells, light treatment led to a 13-fold decrease in the GI50 from 9.5 μM 
to 720 nM (Table 1).  In MDA-MB-231 cells, the GI50 was 601 nM in the light, a 35-fold 
enhancement.  Light alone at the same dose was not growth inhibitory for either cell line 
(Figure 2.9).  When we increased the interval between light pulses, we observed 
diminished potency, consistent with the ability of Azo-CA4 to automatically turn off its 
activity over time (Figure 2.10). 
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Figure 2.7.  Cell viability assays performed using Cell TITER Blue (CTB) fluorescent 
reagent.  HUVECS were seeded at 1500 cells per well (left) and MDA-MB-231 were 
seeded at 10,000 cells per well (right) for six hours.  Combretastatin A4 (Sigma) was 
added to the wells in concentrations from 30 - 0.06 nM (0.25% DMSO) and incubated at 
37°C for 48 hours.  At the end of the incubation period 20μL CTB was added to the 
wells and incubated for an additional 2 hours.  Fluorescence was normalized against 
controls. 
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Figure 2.8. Cell viability assays reported as a percentage of vehicle controls.  Cells 
were treated with varying concentrations of Azo-CA4 for 48 hours and were either 
exposed to 380 nm light (4.4 mW/cm2) for 1 minute every hour (closed circles) or kept in 
the dark (open traingles).  
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Figure 2.9.  Experiments performed to show that light alone is not responsible for cell 
death.  Fluorescence intensity of vehicle control wells after 48 hours of light exposure (1 
minute pulse every hour, 4.4mW/cm2, shown in red) and vehicle control wells kept in the 
dark (black).  At the end of the 48 hour growing period, cells were incubated with CTB 
for 2 hours and read on the BioTek Hybrid S1 plate reader.  Experiments were 
performed in triplicate.  
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Figure 2.10.  Cell viability assays conducted to probe the effects of increasing light 
dosage.  HUVEC were either treated with drugs in 5 replicated wells and shielded from 
light (black circles) or irradiated with 380nm light (4.4mW/cm2) for one minute at the 
beginning of the experiment (green triangles), irradiated for 1 minute every 2 hours (red 
squares), or irradiated for 1 minute every hour (blue crosses).  The GI50 values are 
shown in parentheses in the legend. 
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2.11 Bladder Cancer Assays 
 In addition to the HUVEC and MDA-MB-231 cell lines, a third cell line was 
assayed.  A transitional cell carcinoma cell line (T24) was screened against varying 
concentrations of Azo-CA4.  We chose a bladder cancer cell line because the thin 
nature of the tumors and accesibility of a scope to to irradiate the tumors in a clinical 
setting.  Although there was a clear effect of the drug and an IC50 could be determined, 
cells were surviving at a very high level (~70%) compared to the other cell lines assayed 
(Figure 2.11).  T24 cell lines grew extremely slowly, and the dynamic range of the 
growth inhibitory assay was therefore diminshed.   
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Figure 2.11.  Cell viability assays reported as a percentage of vehicle controls.  Cells 
were treated with varying concentrations of Azo-CA4 for 48 hours and were either 
exposed to 380 nm light (4.4 mW/cm2) for 1 minute every hour (red square) or kept in 
the dark (black circles).  
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2.12 Glutathione Reduction Assays 
The significant gap between the cytotoxicity of CA4 and Azo-CA4 in these cell lines 
suggested that Azo-CA4 may be unstable.  Since azobenzenes are known to react with 
glutathione (GSH),[89, 90] we evaluated the extent to which GSH could inactivate Azo-
CA4 (Figure 4).  Both forms of Azo-CA4 were degraded by GSH over the course of 
several hours.   Interestingly, the light-activated cis-Azo-CA4 compounds were 
degraded more rapidly than trans-Azo-CA4 (Figure 2.12).   
To investigate this further, we treated our compound with light and GSH and 
followed the course of the reaction by LC-MS/MS (Figure 2.13 and Figure 2.14).   As 
expected, the peak corresponding to the cis-Azo-CA4 decreased over time (Figure 
2.13).  Surprisingly, a new peak of the same mass was formed during the reaction.  This 
peak did not co-elute with trans-Azo-CA4 (Figure 2.13), and therefore must be due to a 
rearrangement product or products.  (Note also that the samples were irradiated with 
light immediately prior to injection which would have eliminated the majority of the trans 
isomer even if was present beforehand).  Additionally, transient formation of a peak of 
624 Da was observed during the reaction. The MS-MS fragmentation of this peak 
showed neutral loss peaks of 307, 275, and 129, all of which are characteristic for GSH 
adducts (Figure 2.15).[91]  The 624 peak was not present in a control reaction lacking 
Azo-CA4 (Figure 2.16), lending credence to the fact that this species is an adduct of 
glutathione and Azo-CA4. 
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Figure 2.12.  Glutathione exposure in light.  Azo-CA4 (300 μM in 5.7% DMSO / PBS pH 
7.2) in the presence of fully reduced glutathione (10 mM in PBS pH 7.2) and TCEP (5 
mM in PBS pH 7.2) was placed in 3 separate wells (100 μL / well) of a 96 well plate at 
37°C and (a) exposed to light (380 nm, 4.4 mW/cm2) for 1 min every 2 h.  Absorbance 
spectra were taken at different time points directly preceding exposure to light and are 
expressed as an average of triplicate readings.  (b) is identical to (a) except the reaction 
was kept in the dark, and the Azo-CA4 concentration was 400 μM.  (c) and (d) plot the 
change absorbance of 380 nm over time of the data in (a) and (b) compared to identical 
reactions lacking glutathione.  The decrease in absorbance of the minus GSH control in 
(c) is due to incomplete relaxation back to the trans state.  
 
 
41 
 
 
Figure 2.13.  Azo-CA4 (300 μM in 5.7% DMSO / PBS pH 7.2) in the presence of fully 
reduced glutathione (10 mM in PBS pH 7.2) and TCEP (5 mM in PBS pH 7.2) was 
placed in 3 separate wells (100 μL / well) of a 96 well plate at 37°C and exposed to light 
(380 nm, 4.4 mW/cm2) for 1 min every 2 h immediately preceding analysis.  At the times 
given, a sample was removed and injected onto an analytical column containing 5um 
phenyl C-18 YMC and analyzed by ESI-MS.  (a) Traces for ions of M+H identical to 
Azo-CA4 (319 Da). (b) Traces corresponding to M/Z of 624 Da.  Slight retention time 
drifts are expected due to manual loading of the capillary containing sample onto the 
instrument. 
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Figure 2.14.  (a)  LC-MS chromatogram of a mixture of cis and trans Azo-CA4.  Peaks 
of corresponding to a mass of 319 Da are shown.  Based on comparisons with other 
LC-MS experiments, the trans isomer has a retention time of 13.1 and the cis isomer 
has a retention time of 15.1.  (b) MS/MS spectrum of the 319 Da peak with retention 
time of 13.1 min. (c) MS/MS spectrum of the 319 Da peak with retention time of 15.1 
min.  
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Figure 2.15.  (a) and (b) repeated from Figure 2.14 above and highlight the 319 and 
614 Da peaks respectively.  (c) MS/MS spectrum of the 319 Da peak sampled at 11.88 
min (t = 4 h). (c) MS/MS spectrum of the 624 Da peak sampled at 10.90 min (t = 2 h). 
Peaks at 317 (neutral loss of 307), 349 (neutral loss of 275), and 495 (neutral loss of 
129) are all characteristic for glutathione adducts.  
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Figure 2.16.  Evidence that the 319 and 624 Da peaks require Azo-CA4.  Reactions 
were identical to those described in Figure 5, except they lacked Azo-CA4.  No 
significant peaks at 319 or 624 nm were observed.  
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2.13 Discussion 
 During he preparation of our manuscript Borowiak et. al.[92] Published a paper in 
which Azo-CA4 was synthesized and assayed in a similar manner to the work we had 
done.  It was necessary for us to differentiate our work from Borowiak so we began to 
focus on an explanation for diminishing activity of Azo-CA4 over time in cells.  Shortly 
after shifting our focus, a second publication focusing on the synthesis of Azo-CA4 was 
released.[93] 
 The half-life of thermal reversion of Azo-CA4 and its future analogs is a critical 
piece of their potential use as automatic turn-off drugs and tools.[94]  It is therefore 
significant that our values for the half-lives of Azo-CA4 vary significantly from those 
determined by Borowiak et. al. under the same conditions; our value is about 14-fold 
longer (85 min vs. 6.2 min).[95]  Although in cells the half-life of Azo-CA4 can be altered 
by thiols, the cellular environment,[94] and by tubulin binding itself, all of our cell culture 
data supports the longer half-life value.   For example, our measured EC50 values for 
Azo-CA4 with MDA-231 cells are very similar to those determined by Borowiak et. al. on 
this cell line,[95] yet we pulsed with light once per hour, and they pulsed every 15 
seconds.  If the half-life was 6.2 minutes as reported,[95] we should have observed 
significantly weaker potency with our pulse regimen.  
 Glutathione reactions with azobenzenes have been studied on a number of 
systems.  For most azobenzenes, nucleophilic attack of GS- anion on the diazo nitrogen 
gives the intermediate sulfenylhydrazide[96] (Figure 2.17).  The sulfenyl hydrazide is then 
either attacked by a second glutathione anion to displace the reduced hydrazide or is 
hydrolyzed by water to give back the azobenzene plus a sulfenic acid (Figure 2.17).  
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The hydrazide is easily oxidized back to the azobenzene, and therefore, the net result of 
each of these reactions is re-formation of the original trans-azobenzene.  By a similar 
mechanism, glutathione catalyzes the relaxation of cis-azobenzenes back into their 
trans form.[94, 97]   With Azo-CA4; however, our data shows that reaction with glutathione 
leads to the destruction of the azobenzene structure.  This has been observed before by 
Woolley with other electron rich methoxy-substituted azobenzenes.[88-90]  Woolley 
proposed that the enhanced basicity of the electron rich azo nitrogens leads to 
protonation which primes the compound for nucleophilic attack by GSH.  However, this 
proposed mechanism leads to the production of the same sulfenyl hydrazide (Figure 
2.17) that would be expected to result in reversion back to the azobenzene.  We 
measured the pKa of Azo-CA4, and it is below 4.6 (Figure 2.18), so it will not be 
protonated at physiological pH.   Moreover, we did not see any ions corresponding 
either to the mass of the phenylhydrazide or the sulfenylhydrazide during the course of 
the reaction.  Instead, our LC-MS data shows that a transient adduct of Azo-CA4 and 
GSH with a mass of 624 is formed during the GSH reaction.  This mass is two less than 
would be expected for the sulfenyl hydrazide.  The formation of this 624 Da species 
could potentially be explained by nucleophilic attack of the azo nitrogen onto GSSG to 
form the sulfenyl diazo cation.  To test this, we incubated Azo-CA4 with GSSG, but no 
reaction was observed over 18 h (data not shown) which rules out this potential 
mechanism.  One could envision other possibilities for formation of the sulfenyl diazo 
cation, or loss of the two hydrogens via a mechanism involving electrocyclization of the 
two rings.  More work needs to be done to distinguish between these and other 
possibilities.  Importantly, to our knowledge, this type of degradation has only been 
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observed with electron-rich azobenzenes, which suggests that addition of electron 
withdrawing substituents would eliminate or slow the degradation pathway. 
 In summary, Azo-CA4 exhibits remarkable enhancements in potency 
against HUVEC cells that are consistent with its ability to switch into the more toxic cis 
form in the presence of light.  Moreover, over time, Azo-CA4 automatically converts 
back to its less toxic form.  Provided the glutathione reactivity issue can be solved, Azo-
CA4 and future, similar compounds offer the potential for automatic turn-off of drug 
activity in sites distal from the site of activation and thus present a novel means for 
tightly controlling drug potency and antitumor activity. 
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Figure 2.17.  Reactions of azobenzenes with glutathione. Reported reaction cycle of 
azobenzenes with glutathione.  
  
 
 
49 
 
 
Figure 2.18.  Absorbance of Azo-CA4 at different pH values.   Absorbance spectra from 
200-700 nm at different pH values (left).  Absorbance spectra at 380 nm versus pH 
(right).  All experiments were done in duplicate. 
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2.14 Experimental Section 
 
All reagents and solvents were purchased from Sigma-Aldrich, VWR, or Fisher 
Scientific.  Reagents for cellular assays were purchased from ATCC, Invitrogen-Gibco, 
or VWR.  Tubulin polymerization assay kit was purchased from Cytoskeleton Inc.  1H 
NMR spectra and 13C spectra were recorded at room temperature on a Bruker 400 MHz 
Ultrashield Plus.  Proton and Carbon chemical shifts are expressed in parts per million 
(ppm, δ scale) and are referenced to the solvent peak.  UV-Vis experiments were 
carried out on either NanoDrop ND-1000 Agilent 8453 UV/Vis.  Cell Titer Blue (CTB) 
fluorescence was measured on BioTek Synergy H1 Hybrid plate reader.  Samples were 
loaded on a self-packed fused silica (Polymicro Technologies) trap column (360 micron 
o.d. X 100 micron i.d.)  with a Kasil frit packed with 5-15 micron irregular phenyl  C-18 
YMC packing.  The trap column was connected to an analytical column (360 micron o.d. 
X 50 micron i.d.) with a fritted tip at 5 micron or less (New Objective) packed with 5um 
phenyl C-18 YMC packing.  Peptides were trapped and then eluted into a Thermo 
Finnigan LCQ deca XP max mass spectrometer with an acetonitrile gradient from 0 % 
to 80 % over one hour at a flow rate of between 50-150 nl/minute. 
 
UV Lamp Specifications 
The UV lamp used in all studies consisted of a simple aquarium light fixture 
containing two Philips PL-S 9W/2P BLB bulbs.  Light was shined, in all experiments, at 
a consistent distance of 5 cm from the top of plate and was measured to be 
4.4mW/cm2. 
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UV-Vis Absorption Spectroscopy experiments: 
 
Molar extinction coefficient determination.  A 3.14 mM stock solution of Azo-
CA4 was prepared in 23% DMSO in water.  The solution was stirred vigorously and kept 
in the dark.  400 μL of the solution was placed in the each of three tubes and diluted to 
1 mL with water to give a final concentration of 1.26 mM Azo-CA4.  2-fold serial dilutions 
were made and the absorption of each solution was measured on a NanoDrop ND-1000 
spectrophotometer.  The molar absorptivity, based on three independent trials, was 
found to be 19,150 L * mol-1 * cm-1. 
Half-Life of thermal relaxation determination.  A 2 mL solution of 49.8 μM 
Azo-CA4 was prepared in 0.25% DMSO in water. An initial absorbance reading was 
taken before the solution was exposed to light.  The cuvette was illuminated for 1 min 
and the absorbance (380 nm) was measured every minute for 175 minutes thereafter.  
Each reading was subtracted from the initial reading, and the resulting data was fit an 
exponential decay algorithm.   
Azo-CA4 photoswitching integrity assay.  A 63.7 μM solution of Azo-CA4 in 
DMSO was placed in a cuvette in an Agilent 8453 UV/VIS at 37°C for 23 hours.  The 
sample was illuminated for 1 min every 3 hours and the absorbance was measured 
every 5 minutes.   
 
pH sensitivity experiments.  A 183 μM solution of Azo-CA4 in 3.2% DMSO in 50 mM 
phosphate buffer (pH 8.0) was prepared.  The absorption spectrum and pH were 
measured after multiple additions of concentrated HCl.  
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Glutathione reduction assay.  Azo-CA4 (1.05mM) was incubated in the presence of 
Glutathione (GSH, 10mM) and Tris(2-carboxyethyl)phosphine hydrochloride (TCEP, 
5mM in 9.5% DMSO in PBS.  Azo-CA4 samples were exposed to light for 1 minute 
every hour for 20 hours or were kept in the dark.  Absorption spectra were taken at 
various time points on a NanoDrop.  All experiments were done in triplicate. 
 
In-vitro Tubulin Polymerization.  A fluorescence In-vitro tubulin polymerization assays 
using porcine tubulin were conducted using a fluorescence based polymerization assay 
kit (Cat. #BK011P; Cytoskeleton, Denver, CO) and following the manufacturers 
protocol.  A 96 well plate was warmed to 37°C for 30 min prior to beginning the 
experiment.  Tubulin polymerization buffer was prepared at 4°C by mixing 750 μL 
General Tubulin Buffer (80 nM PIPES ph 6.9, 2mM MgCl2, 0.5 mM EGTA as final 
concentrations) with 250 μL Tubulin Glycerol Buffer (15% glycerol in General Tubulin 
Buffer at final concentration), and 10 μL GTP stock (1 mM final concentration).  500 μL 
of Tubulin Polymerization buffer was warmed to room temperature and one 200 μL 
tubulin vial was thawed for 1 min in a water bath and then placed on ice.  Tubulin was 
mixed with 420 μL of tubulin polymerization buffer and placed in each of five wells 
contains drug and control. 
Each assay was exposed to varying concentrations of Azo-CA4 (80 μM - 800 
nM) prepared in tubulin polymerization buffer.  Samples were either exposed to light 
(380 nm, irradiated for 1 minute) or kept in the dark.  Irradiated samples of Azo-CA4 
were added to tubulin containing wells directly after exposure to light.  Azo-CA4 
 
 
53 
 
samples kept in the dark were added at the same time and the kinetic assay was 
started immediately and proceeded for 1 hour at 37°C (Ex. 350nm, Em. 435nm).  IC50 
values were calculated as a percentage of assays lacking Azo-CA4 by fitting the points 
to the four parameter logistic equation using SigmaPlot software. 
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Cell culture experiments: 
 
Cell lines and culture conditions.  The HUVEC line was cultured in the 
recommended BASAL media supplemented with VEGF growth factors, 5% Fetal Bovine 
Serum (FBS, Life Technologies), 2% L-glutamine and 1% of a 10,000 Units/mL 
Penicillin and 10,000 μg/mL Streptomycin solution.  The MDA-MB-231 line was cultured 
in DMEM media with supplemented with 10% FBS and 1% of a 10,000 Units/mL 
Penicillin and 10,000 μg/mL Streptomycin solution.  The T24 line was cultured in 
McCoy’s 5a Medium (ATCC) and supplemented with 10% FBS and 1% of a 10,000 
Units/mL Penicillin and 10,000 μg/mL Streptomycin solution. 
Cell viability assays.  Cells (18,750 cells/mL for HUVEC, 125,000 cells/mL for 
MDA-MB-231 and T24 125,000 cells/mL) were seeded in dark, flat bottom 96 well 
plates with clear lids for > 2 hours in 80 μL.  After the growing period, Azo-CA4 and CA4 
were added at varying concentrations in 20μL 0.25% DMSO in media.  Differing 
concentrations of Azo-CA4 (30μM – 58.6nM for experiments in the light and 100μM – 
195nM for experiments in the dark) and CA4 (30nM – 0.059nM) were replicated 5 times 
on each plate.  Cells were incubated with drug for 48 hours with one 96 well plate 
undergoing irradiation at 380nm every hour for 1 minute for the duration of the 
experiment and the kept in the absence of light.  5 wells in each experiment were 
devoted to media with no cells or cells with vehicle.  At the end of the 48 hour time 
period cells were incubated for 2 hours with 20μL Cell Titer Blue reagent (CTB)[98] at 
which time fluorescence was measured on a BioTek Synergy H1 Hybrid plate reader 
(Ex. 560nm, Em. 590nm).  Cell viability was expressed as a percentage of maximum 
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(cells with vehicle) and corrected for background fluorescence of the media and data is 
shown as an average ± S.D. of three independent experiments.  GI50 values were 
calculated using SigmaPlot software using a four parameter logistic equation. 
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2.15 Chemical Synthesis 
 
 
 
3-((tert-butyldimethylsilyl)oxy)-4-methoxynitrobenzene, 2.1.  To a solution of 2-
methoxy-5-nitrophenol (5 g, 29.6 mmol) in DMF (120 mL), TBDMS-Cl (4.90 g, 32.5 
mmol) was added in one portion.  The reaction mixture was stirred vigorously for 3 
hours until TLC showed disappearance of 2-methoxy-5-nitrophenol.  The mixture was 
evaporated and water (80 mL) was added.  This solution was extracted 3 times with 
DCM (80 mL) and the combined organic layers were washed with brine, dried over 
Na2SO4, and evaporated to yield 7.73 g (92.3%) of a brown solid.     
 
1H NMR (400 MHz, CDCl3) δ 7.89 (dd, J = 9.0, 2.8 Hz, 1H), 7.71 (d, J = 2.7 Hz, 1H), 
6.89 (d, J = 9.0 Hz, 1H), 3.92 (s, 3H), 1.01 (s, 9H), 0.19 (s, 6H).  
 
13C NMR (101 MHz,CDCl3) δ 156.76, 145.01, 141.42, 118.40, 116.06 , 110.48 , 55.87 , 
25.60, 18.44, 17.39 , -4.63, -4.92. 
 
HRMS ESI-MS (M + H+) C13H22NO4Si
+ calc. 284.1313 obsd. 284.1314. 
 
 
 
 
57 
 
 
 
3-((tert-butyldimethylsilyl)oxy)-4-methoxyaniline, 2.2.  Compound 2.1 (2 g, 7.1 
mmol) was dissolved in an anhydrous 1:1 mixture of MeOH and EtOH (24 mL) in the 
presence of 10% Pd/C (400 mg, 0.38 mmol) under Ar.  The reaction vessel was purged 
for 20 minutes with H2 gas, sealed, and stirred for 3 h.  The reaction was filtered through 
Celite and evaporated to yield 1.69 g (94.5%) of a dark brown oil.  
 
1H NMR (400 MHz, CDCl3) δ 6.68 (d, J = 8.4 Hz, 1H), 6.28 (d, J = 2.8 Hz, 1H), 6.25 (dd, 
J = 8.4, 2.7 Hz, 1H), 3.72 (s, 3H), 3.30 (s, 2H), 0.99 (s, 9H), 0.15 (s, 6H).   
 
13C NMR (101 MHz, CDCl3) δ 146.12, 144.32, 140.65, 114.43, 109.49, 108.20, 56.62, 
25.76, 18.43, -4.36, -4.64. 
 
HRMS ESI-MS (M + H+) C13H24NO2Si
+ calc. 254.1571. obsd 254.1566.  
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(E)-1-(3-((tert-butyldimethylsilyl)oxy)-4-methoxyphenol)-2-(3,4,5-
trimethoxyphenyl)diazene, 2.3.  Compound 2.2. (1 g, 3.9 mmol) and 3,4,5-
trimethoxyaniline (723 mg, 3.9 mmol) were stirred in freshly distilled CH2Cl2 under Ar.  
(Diacetoxyiodo)benzene (2.54 g, 7.9 mmol) was added in one portion.  The reaction 
was allowed to proceed until the disappearance of compound 2 via TLC (20 minutes). 
The reaction mixture was rotary evaporated and was purified by flash column 
chromatography (100% Hexanes to 20% EtOAc in Hexanes) to yield 107 mg (6.3%) of 
an orange solid.    
 
1H NMR (400 MHz, CDCl3) δ 7.58 (dd, J = 8.6, 2.4 Hz, 1H), 7.45 (d, J = 2.4 Hz, 1H), 
7.21 (s, 2H), 6.96 (d, J = 8.6 Hz, 1H), 3.97 (s, 6H), 3.92 (s, 3H), 3.90 (s, 3H), 1.03 (s, 
9H), 0.20 (s, 6H).   
 
13C NMR (101 MHz, CDCl3) δ 153.82, 153.51, 148.69, 146.99, 145.53, 140.16, 119.41, 
113.35, 111.20, 100.16, 61.02, 56.22, 55.59, 29.71, 25.74, 18.50, 1.03, -4.56. 
 
HRMS ESI-MS (M + H+) C22H33N2O5Si
+ calc. 433.2153. obsd 433.2149. 
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(E)-2-methoxy-5-((3,4,5-trimethoxyphenyl)diazenyl)phenol, 2.4.  To a solution of 
compound 2.3 (53.5 mg, 0.12 mmol) in DMF (4 mL) potassium fluoride hydrate (81.6 
mg, 1.4 mmol) and AcOH (20 μL, 0.35 mmol) were added.  The reaction was complete 
after 1 hour as monitored via TLC.  The reaction mixture was evaporated to yield an 
orange powder.  The powder was dissolved in 5 mL DCM and washed with H2O (3 x 5 
mL), once with brine, and dried over Na2SO4.  The organic layer was purified by flash 
column chromatography (100% Hexanes to 20% EtOAc in Hexanes) to yield 20.6 mg 
(53.9%) of a waxy orange solid.   
 
1H NMR (400 MHz, CDCl3) δ 7.56 – 7.51 (m, 2H), 7.22 (s, 2H), 6.98 (d, J = 8.3 Hz, 1H), 
5.72 (s, 1H), 3.98 (s, 3H), 3.96 (s, 6H), 3.93 (s, 3H).   
 
13C NMR (101 MHz,CDCl3) δ 153.53, 149.20, 148.56, 147.44, 146.23, 140.32, 118.92, 
110.09, 106.16, 100.26, 61.02, 56.20. 
 
HRMS ESI-MS (M + H+) C16H19N2O5 calc. 319.1288. obsd 319.1299. 
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Failed Synthesis, Route 1.  2,4,5-trimethoxyaniline (3eq) was dissolved in DMF.  KOH 
(10eq) was added to the reaction mixture and it was stirred until all of the solid 
dissolved.  To the reaction mixture was added 2-methoxy-5-nitrophenol (1eq).  The 
reaction mixture was attached to a reflux condenser and heated at 150oC for 24 hours.  
After 24 hours the reaction was checked by TLC.  No new products were seen.  The 
reaction was allowed to continue for 6 days and monitored by TLC.  No new product 
was observed. 
  
 
 
61 
 
 
Failed Synthesis, Route 2.   
Step 1:  2.1 was prepared in the same way as reported above. 
Step 2: 2,4,5-trimethoxyaniline (3eq) was dissolved in DMF.  KOH (10eq) was added to 
the reaction mixture and it was stirred until all of the solid dissolved.  To the reaction 
mixture was added 2-methoxy-5-nitrophenol-TBDMS (1eq).  The reaction mixture was 
attached to a reflux condenser and heated at 150oC for 24 hours.  After 24 hours the 
reaction was checked by TLC.  No new products were observed.  The reaction was 
allowed to continue for 6 days and monitored by TLC.  No new product was observed. 
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2.16 Summary 
 In summary, a novel photoswitching drug with reversible photoactivation and GI50 
values in the mid-nM range has been prepared.  In the future, it may be possible to 
control the amount of glutathione in the cell by administration GSH synthesis inhibitor.  
Also, we may be able to increase the toxicity of Azo-CA4 by coadministration with 
another mitotic inhibitor such as paclitaxel or by creating an electron withdrawing 
derivative. 
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CHAPTER 3. FOLATE RECEPTOR-α MEDIATED AND PHOTOCLEAVABLE DRUG 
DELIVERY 
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3.1 Introduction 
 There are a number of ways that light has been used to specifically deliver a 
payload to a cancer cell.  One of these ways involves the use of micelles, containing a 
cargo, with some type of chromophore that disrupts electrostatic interaction of the 
amphiphilic block copolymers, which is necessary for micelle formations, upon 
absorption of a specific wavelength.[99]  When these micelles are decorated with a 
cancer specific ligand, dual targeting is achieved.  Azobenzene is an example of these 
chromophores that can change conformation to destabilize micelle structure.  Similar to 
light-responsive micelles are liposomes, which consist of concentric bilayers containing 
phospholipids.  Liposomes, like micelles, can carry a cargo such as doxorubicin.  
Research is being conducted in to destabilizing the lipid bilayer, usually decorated with 
a targeting ligand, through an outside energy source (irradiation) to trigger drug release 
in the vicinity of a target.[100]  Light-activated drug delivery through conjugation to light 
sensitive nanomaterials is also being researched.  For example, silica nanoparticles 
expressing targeting ligands are biocompatible and contain light sensitive functionalities 
for the controlled release of drugs.[101] Finally, direct conjugation of a drug through a 
photocleavable linker to a cancer specific ligand is being researched. 
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3.2 Designing Dual Specificity Drug Conjugates 
 Our dual-specificity drug delivery system uses three parts (Figure 3.1).  First and 
foremost, a cancer specific ligand is needed.   Next, you need a drug.  Lastly, a 
photocleavable linker molecule between the drug and ligand (or cell impermeable 
molecule) is required.  The cancer-specific ligand has affinity for some phenotype of 
cancer cells.  Usually this is the overexpression of cell-surface receptors.  When we 
attach this to Doxorubicin through a light cleavable molecule, we now have a drug 
conjugate that is not only specific for the cancer cell through the ligand, but also cannot 
offer toxicity without the introduction of some external radiation source. 
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Figure 3.1.  Ligand targeted, photocleavable drug release allowing for passive diffusion 
in the vicinity of the target.  
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3.2.1 Cancer Specific Ligand-Folic Acid Conjugates 
  Many types of cancers over express folate receptor-α (FR-α) on the cell 
surface.[6]  For this reason we hypothesized that conjugation of folic acid to doxorubicin 
through a photocleavable linker would present a novel way to achieve dual targeting of 
cancer cells. 
 During our literature searches for the synthesis of folic acid conjugates, we 
discovered what we thought was an nonselective way to synthesize these conjugates, 
usually through a carbodiimide coupling.[102-104]  Folic acid contains a pteroic acid moiety 
attached to a glutamic acid moiety.  The glutamic acid moiety contains two carboxylic 
acid units, which are both reactive to carbodiimide coupling methods.  Because it is 
known that the alpha carboxylic acid unit is important in binding FRα, wanted a method 
for selective attachment at the gamma-carboxylic acid.[105]  Therefore, we decided to 
synthesize folic acid in two pieces (Scheme 3.1 and 3.2).  The first piece is the glutamic 
acid moiety of folic acid and the second piece is a pteroyl azide.  We started by 
functionalizing the γ-carboxylic acid of glutamic acid with 3.3.  We achieved the 
chemoselectively with Boc protection at off-target carboxylic acids.  After deprotection of 
the propargyl functionalized glutamic acid we were able to attach it to pteroyl azide. 
 Pteroyl azide was prepared in a multistep synthesis.  We started with cyclicaztion 
of the glutamic acid moiety with trifluoroacetic anhydride (3.4).  Subsequently, we used 
a hydrolysis step to yield 3.5 and nucleophilic attack by hydrazine to remove the 
glutamic acid moiety and yield 3.6.  tert-Butyl nitrite and isothicyanate were employed to 
yield pteroyl aizde, 3.7. 
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Scheme 3.1.  Total synthesis of a folic acid analog for click chemistry.  
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Scheme 3.2.  Total synthesis of a folic acid analog for click chemistry.  
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3.2.2 EDANS Conjugates  
Negatively charged molecules struggle to cross cellular membranes.  Negative-
negative electrostatic interactions between phospholipids in a cellular membrane and 
the sulfonic acid moiety of Ethylenediaminonapthalenesulfonic acid (EDANS) molecule 
will keep EDANS and anything attached to it from entering a cell.  However, upon 
irradiation of a photocleavable linker, a payload may passively diffuse through the cell.  
This work has been reported previously[5] and in this work the synthesis was optimized 
and scaled up in order to perform experiments with mouse tumor xenografts. 
My main goal during the synthesis of this previously reported compound was to 
enhance yields during each step.  Improved yields were recorded for each step of the 
multi-step synthesis.  Mostly, improved yields were achieved by carefully transferring 
between glassware during extractions and other purification steps.  However, during the 
reaction with Bis-PNP, going from 3.13 to 3.14, yields were improved by changing the 
order of addition.  Originally, Bis-PNP was added to a stirring solution of 3.13, but yields 
were improved by adding 3.13 to a concentrated stirring solution of Bis-PNP.  
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Scheme 3.3.  Total synthesis of Dox-EDANS  
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3.3 Discussion 
 We anticipate that the effectiveness of photocaged permeability will translate to 
mouse xenografts.  The carefully synthesized EDANS-DOX conjugate was prepared 
with improved yields at every step of the synthesis. 
 
3.4 Experimental Section 
All reagents and solvents were purchased from Sigma-Aldrich, VWR, or Fisher 
Scientific.   1H NMR spectra and 13C spectra were recorded at room temperature on 
a Bruker 400 MHz Ultrashield Plus.  Proton and Carbon chemical shifts are expressed 
in parts per million (ppm, δ scale) and are referenced to the solvent peak (DMSO) or 
TMS (CDCl3). 
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3.5 Chemical Synthesis[106] 
 
 
 
Bis-p-tosyltriethylene glycol, 3.1.  Triethylene glycol (1.68 g, 11 mmol) and p-tosyl 
chloride (4.26 g, 22 mmol) were dissolved in CH2Cl2 (25 mL) and stirred.  The reaction 
mixture was cooled on ice and KOH (5.37 g, 96 mmol, powdered) was added in portions 
over a period of 5 minutes.  After 4 hours, 150 mg of additional p-tosyl chloride was 
added.  After 5 hours, the reaction appeared complete via TLC (1:1 / EtOAc:Hexanes).  
The reaction mixture was added to a separatory funnel along with H2O (30 mL).  The 
aqueous layer was washed twice with CH2Cl2 (30 mL) and dried over sodium sulfate to 
yield 4.5g (87.7%) of a white solid.  1H NMR is in agreement with previous reports.[107] 
1H NMR (400 MHz, DMSO-d6) δ 7.80 – 7.75 (m, 4H), 7.47 (d, J = 8.1 Hz, 4H), 4.12 – 
4.07 (m, 4H), 3.56 – 3.51 (m, 4H), 3.38 (s, 4H), 2.41 (s, 6H). 
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Bis-azidetriethylene glycol, 3.2.  Compound 3.1 (4.437g, 10mmol) was suspended in  
DMF (15 mL) and NaN3 (1.3g, 20mmol) was added to it.  The reaction mixture was 
stirred in an oil bath at 80°C for 1 hour at which time TLC (3:2 / Hexanes:EtOAc) with 
PPh3 and ninhydrin stain indicated that only the bis-azide was present.  The DMF was 
evaporated on high vacuum overnight.  The white solid was suspended in diethyl ether, 
filtered, and evaporated  to yield 1.5 g (77.3%) of colorless oil. 1H NMR is in agreement 
with previous reports.[108] 
 
1H NMR (400 MHz, DMSO-d6) δ 3.65 – 3.58 (m, 4H), 3.58 (s, 4H), 3.39 (dd, J = 5.6, 4.3 
Hz, 4H). 
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2-(2-(2-azidoethoxy)ethoxy)ethanamine, 3.3.  Compound 3.2 (500mg, 2.5mmol) was 
dissolved in a 10 mL solution (5:1:4 / Et2O:THF:1.5M HCl) in an argon environment 
sustained by pressure from a balloon.  A solution of PPh3 (655.1mg, 2.5mmol) in Et2O 
(5 mL) was added via syringe over a period of 5 minutes.  The reaction mixture was 
stirred at room temperature for 18 hours.  4M HCl (3 mL) was added and the aqueous 
layer was extracted 7 times with CH2Cl2 (20 mL) until no UV absorbing spots were 
observed on TLC.  10 pellets of KOH were added the raise the pH to ~14 and the 
aqueous layer was extracted 3 times with CH2Cl2 (20 mL).  The organic layer was 
evaporated to yield 82.4 mg (18.8%) of a colorless oil.  1H NMR is in agreement with 
previous reports.[108] 
 
1H NMR (400 MHz, Chloroform-d) δ 3.67 (m, J = 12.9, 7.3, 6.1, 3.3 Hz, 6H), 3.52 (m, J 
= 5.2, 2.0 Hz, 2H), 3.39 (t, J = 5.1 Hz, 2H), 1.61 (s, 2H). 
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N 2,10-Bis(trifluoroacetyl)pyrofolic acid/anhydride, 3.4.  To a stirred suspension of 
folic acid (2g, 4.53mmol) in anhydrous THF (20 mL) was slowly added trifluoroacetic 
anhydride (5.12mL, 36.8mmol) at 0 C.  The reaction was warmed to room temperature 
and stirred overnight (12 h).  The solution was concentrated by rotary evaporation and 
the thick, brown oil was added to a stirring solution of toluene (200 mL) with the aid of 
THF (2 mL).  The yellow precipitate was collected by vacuum filtration (water aspirator).  
The solid was washed with Et2O (10mL) to yield 1.85g (61.2%) of a yellow solid.  
1H 
NMR is in agreement with previous reports.[106] 
 
1H NMR (400 MHz, DMSO-d6) δ 9.30 (s, 1H), 8.62 (s, 2H), 7.58 (d, J = 8.7 Hz, 2H), 
7.11 (s, 4H), 6.86 (t, J = 6.1 Hz, 1H), 6.61 (d, J = 8.7 Hz, 2H), 4.46 (d, J = 6.0 Hz, 3H). 
 
19F NMR (d6-DMSO)   -66.13, -74.3, -75.02 
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N10-(Trifluoroacetyl)pyrofolic acid, 3.5.  To a stirring solution of 3.4 (1.6 g, 2.6mmol) 
in THF (10 mL) was added ~10 g of crushed ice.  The solution was allowed to warm to 
room temperature and stirred overnight (15 h).  The mixture was slowly added to stirred 
Et2O (40 mL).  The precipitate was collected by vacuum filtration (water aspirator), 
washed with Et2O (10 mL) and dried overnight under high vacuum to yield 1.23g (57% 
from folic acid) of a yellow powder.  1H NMR is in agreement with previous reports.[106] 
 
1H NMR (400 MHz, DMSO-d6) δ 8.64 (d, J = 3.6 Hz, 1H), 7.63 (s, 4H), 7.04 (s, 2H), 
5.13 (s, 2H), 4.73 (dd, J = 8.9, 4.2 Hz, 1H), 2.62 – 2.39 (m, 3H), 2.04 (dd, J = 10.5, 5.3 
Hz, 1H). 
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Pteroyl hydrazide, 3.6.   Compound 3.5 (1g, 1.92mmol) was dissolved in DMSO 
(20mL) and hydrazine monohydrate (1.46mL, 30.1mmol) was added dropwise via 
syringe pump with stirring while maintaining the reaction temperature at 25 C with the 
aid of an external water bath.  The reaction was stirred overnight at room temperature 
(15 hours).  MeOH (28 mL) was slowly added to the stirring reaction mixture.  The 
precipitate was collected by vacuum filtration, washed with MeOH (15mL x 3) and Et2O 
(15 mL x 3), and dried under high vacuum overnight to yield 515.1 mg (82%) as a 
yellow solid.  1H NMR is in agreement with previous reports.[106] 
 
1H NMR (300 MHz, d6-DMSO): δ 9.30 (s, 1H), 8.62 (s, 1H), 7.58 (d, J = 8.7 Hz, 2H), 
7.11 (s, 3H), 6.86 (t, J = 6.1 Hz, 1H), 6.61 (d, J = 8.7 Hz, 2H), 4.46 (d, J = 6.0 Hz, 2H). 
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Pteroyl azide, 3.7.   Compound 3.5 (250mg, 0.77mmol) was placed in a round bottom 
flask with cat. KSCN (3.8mg, 0.04mmol).  The flask was cooled to -10°C via brine and 
ice and ice cold TFA (2 mL) was added to the round bottom.  The reagents were 
allowed to dissolve and tBuONO (91.1μL, 0.77mmol) was added dropwise via syringe 
pump.  The reaction was stirred at -10 C for 7 h and allowed to warm to room 
temperature.   2-propanol (4 mL) was slowly added to afford an orange precipitate that 
was collected by centrifugation (30 min x 5,000 rpm).  The pellet was washed with H2O 
(4 mL),acetonitrile (4 mL), and Et2O (4 mL), centrifuging after each wash (30 min x 
5,000 rpm). The pellet was dried under high vacuum for 24 hours to give 204.3 mg 
(79%) of an orange solid.  1H NMR is in agreement with previous reports.[106] 
 
1H NMR (300 MHz, d6-DMSO):  8.69 (s, 1H), 7.69 (d, J = 8.8 Hz, 2H), 7.29 (s, 3H), 
6.71 (d, J = 8.9 Hz, 2H), 4.56 (s, 2H). 
  
 
 
80 
 
 
 
Boc-Glu-OtBu-NHS, 3.8.  Boc-Glu-OtBu (100mg, 0.33mmol) was dissolved in  DMF (5 
mL).  EDC (95mg, 0.50mmol) and N-hydroxysuccinimide (57mg, 0.50mmol) were added 
to the reaction mixture and stirred vigorously overnight (15 h).  The reaction mixture was 
rotary evaporated.  EtOAc (10 mL) was added and subsequently washed with H2O (4 x 
10mL).  The organic layer was evaporated to yield 126 mg (95%) of a white solid.  1H 
NMR is in agreement with previous reports.[109] 
 
1H NMR (400 MHz, Chloroform-d) δ 5.23 (d, J = 8.6 Hz, 1H), 2.83 (s, 4H), 2.70 (dd, J = 
16.0, 9.9, 6.1 Hz, 2H), 2.27 (td, J = 9.2, 4.9 Hz, 1H), 2.08 – 1.98 (m, 1H), 1.48 (s, 9H), 
1.45 (s, 9H). 
 
  
 
 
81 
 
 
Boc-Glu-OtBu-TEG-azide, 3.9.  Compound 3.8 (80mg, 0.20mmol) was dissolved in 
DMF (2 mL).  Triethylamine (28μL, 0.20mmol) and compound 3.3 (31.4mg, 0.18mmol) 
were added and the reaction mixture was stirred for 3 h.  The reaction mixture was 
rotary evaporated and EtOAc (10 mL) was added.  The organic layer was washed with 
H2O (3 x 10mL), citric acid (10 mL), brine solution (10 mL), and dried over sodium 
sulfate.  The organic layer was then rotary evaporated to yield 80mg (87%) of a white 
solid. 
1H NMR (400 MHz, DMSO-d6) δ 7.82 (s, 1H), 7.06 (d, J = 7.7 Hz, 1H), 3.77 (d, J = 4.7 
Hz, 0H), 3.59 (d, J = 5.2 Hz, 2H), 3.54 (d, J = 7.5 Hz, 2H), 3.43 – 3.36 (m, 4H), 3.31 (s, 
2H), 3.19 (d, J = 5.8 Hz, 2H), 2.13 (t, J = 7.8 Hz, 2H), 1.92 – 1.81 (m, 1H), 1.77 – 1.65 
(m, 1H), 1.38 (d, J = 4.3 Hz, 18H). 
13C NMR (101 MHz, DMSO-d6) δ 171.51, 171.35, 155.43, 79.07, 69.41, 53.98 , 50.00, 
38.49 , 31.60, 27.86, 26.63 . 
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Glu-TEG-Azide, 3.10.  Compound 3.9 (80mg, 0.17mmol) was dissolved in 30% 
TFA/CH2Cl2 (v/v) (2 mL) at 0°C.  The reaction was stirred for 1 h and was then allowed 
to warm to room temperature and stirred for an additional 2 h at which point TLC (1:1 / 
EtOAc:Hexanes) with PPh3/Ninhydrin stain indicated complete consumption of starting 
material.  The reaction mixture was rotary evaporated to yield 53mg (100%) of a white 
solid.  1H NMR is in agreement with previous reports.[110] 
 
1H NMR (400 MHz, DMSO-d6) δ 8.02 (t, J = 5.6 Hz, 1H), 3.84 (t, J = 6.4 Hz, 1H), 3.62 – 
3.47 (m, 4H), 3.47 – 3.30 (m, 3H), 3.20 (d, J = 5.8 Hz, 1H), 2.28 (ddd, J = 14.1, 8.6, 6.4 
Hz, 1H), 1.98 (ddd, J = 12.8, 5.9, 2.6 Hz, 1H). 
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Failed synthesis of Folic-TEG-Azide, 3.11.  Compound 3.10 (53mg, 0.17mmol) was 
dissolved in anhydrous DMSO (2 mL) and triethylamine (73μL, 0.51mmol) was added to 
the reaction mixture.  The reaction mixture was stirred and compound 3.7 (65 mg, 
0.19mmol) was added in one portion.  The reaction was allowed to proceed overnight 
(18 h) with vigorous stirring.  Acetonitrile (6 mL) was added and the yellow precipitate 
was collected by centrifugation (30min x 5,000 rpm).  The pellet was washed with 1% 
HCl (6 mL), acetonitrile (6 mL), and diethyl ether (6 mL) with centrifugation after each 
wash.  The resulting solid was dried under high vacuum overnight to yield 2.7 mg 
(2.5%).  1H NMR was inconclusive as solvent peaks made visibility of the dilute product 
difficult to decipher. 
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2,5-dioxopyrrolidin-1-yl 4-(4-(1-hydroxyethyl)-2-methoxy-5-
nitrophenoxy)butanoate, 3.12.  4-(4-(1-hydroxyethyl)-2-methoxy-5-
nitrophenoxy)butanoic acid (nitroveratryl photolinker, 400mg, 1.34mmol) was dissolved 
in DMF (20 mL) and shielded from ambient light with aluminum foil.  The solution was 
cooled to 0°C and stirred for 10 min.  EDC (312mg, 2.00mmol) and NHS (230mg, 
2.00mmol) were added and the reaction mixture was stirred overnight (12 h), slowly 
warming to room temperature.  DMF was rotary evaporated and EtOAc (10 mL) was 
added to the reaction vessel.  The organic layer was washed with H2O (4 x 20mL),brine 
(20 mL), dried over sodium sulfate, and rotary evaporated to yield 502mg (95%) of a 
yellow solid.  1H NMR is in agreement with previous reports.[5] 
 
1H NMR (400 MHz, DMSO-d6) δ 7.55 (s, 1H), 7.37 (s, 1H), 5.46 (t, J = 4.2 Hz, 1H), 5.26 
(dd, J = 6.3, 3.5 Hz, 1H), 4.13 (t, J = 6.4 Hz, 2H), 3.91 (s, 3H), 2.82 (s, 6H), 2.61 – 2.57 
d(m, 2H), 2.09 (t, J = 6.9 Hz, 2H), 1.37 (d, J = 6.3 Hz, 4H). 
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4-(4-(1-hydroxyethyl)-2-methoxy-5-nitrophenoxy)-N-(prop-2-yn-1-yl)butanamide, 
3.13.  Compound 3.12 (400mg, 1.0mmol) was dissolved in DMF (8 mL) and stirred at 
room temperature.  In a separate vessel, propargylamine (129μL, 2.0mmol) and TEA 
(281μL, 2.0mmol) were dissolved in DMF (1 mL).  The propargylamine/TEA solution 
was added dropwise to the reaction mixture containing 3.12 over a period of 10 min.  
The reaction mixture was shielded from ambient light via aluminum foil and stirred 
overnight (18 h).  DMF was rotary evaporated and EtOAc (30 mL) was added to the 
flask and washed with H2O (4 x 20mL),brine (20 mL), dried over sodium sulfate, and 
rotary evaporated to yield 296mg (87%) of a yellow solid.  1H NMR is in agreement with 
previous reports.[5] 
 
1H NMR (400 MHz, DMSO-d6) δ 8.33 – 8.28 (m, 1H), 7.53 (s, 1H), 7.37 (s, 1H), 5.47 (s, 
1H), 5.27 (q, J = 6.2 Hz, 1H), 4.05 (t, J = 6.4 Hz, 2H), 3.92 (s, 3H), 3.86 (dd, J = 5.5, 2.5 
Hz, 2H), 3.07 (t, J = 2.5 Hz, 1H), 2.28 (t, J = 7.4 Hz, 2H), 1.96 (p, J = 6.8 Hz, 2H), 1.38 
(d, J = 6.2 Hz, 3H).  
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1-(5-methoxy-2-nitro-4-(4-oxo-4-(prop-2-yn-1-ylamino)butoxy)phenyl)ethyl (4-
nitrophenyl) carbonate, 3.14.  Bis(4-nitrophenyl) carbonate (543mg, 1.78mmol) was 
dissolved in DMF (5 mL) and stirred at room temperature.  In a separate vessel, 
compound 3.13 (200mg, 0.59mmol) and TEA (166μL, 1.19mmol) were dissolved in 
DMF (5 mL) and added dropwise over a period of 30 min to the solution containing 
bis(4-nitrophenyl) carbonate.  The reaction mixture was allowed to stir overnight (10 h), 
shielded from the light via aluminum foil.  DMF was rotary evaporated and 1% HCl (20 
mL) was added to the resulting oil.  The mixture was extracted with EtOAc (30 mL).  
The organic layer was collected and washed with a saturated NaHCO3 solution (3 x 20 
mL), brine (20 mL), dried over sodium sulfate, and rotary evaporated to yield 198 mg 
(68%) of a yellow solid.  1H NMR is in agreement with previous reports.[5] 
 
1H NMR (400 MHz, DMSO-d6) δ 8.29 (d, J = 9.2 Hz, 2H), 7.59 (s, 1H), 7.53 (d, J = 9.2 
Hz, 2H), 7.19 (s, 1H), 6.28 (q, J = 6.4 Hz, 1H), 4.08 (t, J = 6.4 Hz, 2H), 3.96 (s, 3H), 
3.85 (dd, J = 5.5, 2.6 Hz, 2H), 3.06 (t, J = 2.5 Hz, 1H), 2.27 (t, J = 7.4 Hz, 2H), 1.96 (t, J 
= 7.0 Hz, 2H), 1.72 (d, J = 6.4 Hz, 3H). 
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Dox-NV-alkyne, 3.15.  Doxorubicin (104mg, 0.18mmol) was dissolved DMF (3 mL) 
containing TEA (56μL, 0.76mmol) and stirred in a foil-covered flask.  Compound 3.14 
(100mg, 0.20mmol) was added to the reaction mixture in one portion and allowed to stir 
overnight (15 h).  DMF was rotary evaporated and EtOAc (30 mL) was added to the 
vessel.  The organic layer was washed with H2O (4 x 20 mL), brine (20 mL), dried over 
sodium sulfate, and rotary evaporated.  The oil was dissolved in a minimal amount of 
EtOAc and purified by silica flash column chromatography (100% EtOAc → 1:9 / 
MeOH:EtOAc) to yield 107 mg (66%) of a deep red oil. 1H NMR is in agreement with 
previous reports.[5] 
 
1H NMR (400 MHz, DMSO-d6) δ 14.01 (d, J = 18.5 Hz, 2H), 13.25 (d, J = 7.6 Hz, 2H), 
7.90 (t, J = 5.8 Hz, 4H), 7.64 (q, J = 5.4 Hz, 2H), 7.53 (s, 1H), 7.48 (s, 1H), 7.16 (s, 1H), 
7.12 (s, 1H), 6.09 – 6.02 (m, 1H), 5.38 (d, J = 5.1 Hz, 1H), 5.21 (d, J = 8.0 Hz, 1H), 4.94 
(s, 1H), 4.81 – 4.73 (m, 2H), 4.62 (d, J = 5.8 Hz, 1H), 4.55 (d, J = 5.7 Hz, 3H), 4.14 – 
3.76 (m, 25H), 2.30 – 2.06 (m, 8H), 2.02 – 1.78 (m, 6H), 1.52 – 1.43 (m, 7H), 1.11 (dd, J 
= 9.2, 6.3 Hz, 6H). 
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2,5-dioxopyrrolidin-1-yl 4-azidobenzoate, 3.16.  4-azidobenzoic acid (500mg, 
3.06mmol) was dissolved in DMF (15 mL).  EDC (881mg, 4.60mmol) and NHS (529mg, 
4.60mol) were added to the reaction mixture and stirred overnight (10 h).  DMF was 
rotary evaporated and EtOAc (20 mL) was added to the reaction vessel.  The organic 
layer was washed with H2O (4 x 20 mL), brine (20 mL), dried over sodium sulfate, and 
rotary evaporated to yield 796mg (99%) of an off-white solid.  1H NMR is in agreement 
with previous reports.[5] 
 
1H NMR (300 MHz, DMSO-d6) δ 8.13 – 8.07 (m, 2H), 7.38 – 7.30 (m, 2H), 2.88 (s, 4H). 
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5-((2-(4-azidobenzamido)ethyl)amino)naphthalene-1-sulfonic acid, 3.17.  To a 
stirred solution of 3.16 (53.7mg, 0.21mmol) in 5mL DMF, TEA (39.2μL, 0.28mmol) was 
added.  EDANS (50mg, 0.19mmol) was then added to the reaction mixture and stirred 
overnight (15 h).  DMF was rotary evaporated and CH2Cl2 (10 mL) was added to the 
resulting oil.  The organic layer was washed with H2O (3 x 10 mL), brine (10 mL), dried 
over sodium sulfate and rotary evaporated.  The product was redissolved in a minimal 
amount of CHCl3 and purified by silica flash column chromatography (15:85 / 
MeOH:CHCl3) to yield 50mg (64%) of a brown solid. 
1H NMR is in agreement with 
previous reports.[5] 
 
1H NMR (400 MHz, DMSO-d6) δ 8.79 (t, 1H), 8.16 (d, 2H), 7.95 (d, J = 8.7 Hz, 2H), 7.31 
(ddd, J = 23.7, 8.6, 7.4 Hz, 3H), 7.22 (d, J = 8.6 Hz, 2H), 6.67 – 6.63 (m, 1H), 3.61 (d, J 
= 6.2 Hz, 2H), 3.48 – 3.29 (m, 5H), 3.07 (dd, J = 7.3, 4.8 Hz, 2H). 
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Dox-NV-EDANS, 3.18.  Stock solutions of all reagents were freshly prepared 
immediately before the experiment.  500μL of compound 3.17 (100mM in DMSO), 
500μL compound 3.15 (100mM in DMSO), and 500μL TBTA ligand (10mM in DMSO) 
were stirred at room temperature in a round bottom flask protected from ambient light 
via aluminum foil.  500μL sodium ascorbate (100mM in water) and 500μL copper sulfate 
(20mM in water) were then added to the reaction mixture.  The reaction was stirred for 
72 hours until TLC indicated completion (1:4 / MeOH:CHCl3).  The reaction mixture was 
concentrated, filtered and purified on RP-HPLC using 20% acetonitrile (0.1% TFA in 
H2O) for 10 minutes followed by a gradient of acetonitrile concentration from 20% to 
70% over 30 minutes at 6mL/min.  The fractions (~15mL each) were collected in to 
tubes containing 500 μL of ammonium bicarbonate (2mg/mL) to quench TFA.  A mixture 
of diastereomers eluted at 26.5 and 28.5 min) comparable to the literature.[5]  The 
aforementioned fractions were collected, combined and lyophilized to yield 10mg (73%) 
of a deep red solid.  1H NMR is in agreement with the previously reported compound.[5] 
1H NMR (400 MHz, DMSO-d6) δ 14.05 (s, 1H), 13.28 (s, 1H), 8.85 (t, J = 5.9 Hz, 2H), 
8.71 (s, 1H), 8.45 (d, J = 5.4 Hz, 2H), 8.05 (d, J = 15.4 Hz, 5H), 7.92 (d, J = 6.5 Hz, 4H), 
7.54 (s, 1H), 7.40 – 7.21 (m, 8H), 7.00 (d, J = 8.0 Hz, 1H), 6.65 (d, J = 7.6 Hz, 2H), 6.05 
(d, J = 6.4 Hz, 1H), 5.22 (s, 1H), 4.95 (s, 1H), 4.54 (s, 3H), 3.96 (d, J = 29.1 Hz, 8H), 
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3.62 (d, J = 6.0 Hz, 3H), 3.43 (d, J = 6.3 Hz, 3H), 2.97 (s, 2H), 2.35 – 1.74 (m, 7H), 1.45 
(d, J = 6.6 Hz, 5H), 1.09 (d, J = 6.5 Hz, 4H). 
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CHAPTER 4. TARGETING THE ACIDIC EXTRACELLULAR ENVIRONMENT OF 
CANCER 
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4.1 Introduction 
 Since the discovery of the translocation of the HIV-1 Tat protein, there have been 
many attempts to discover which parts of the protein are responsible for cell 
permeability.[48]  It was later found that permeable, truncated portions of Tat contained a 
large number of positively charged residues, especially L-arginine.  From there, it has 
been shown that arginine homopolymers are effective at entering cells.[111]  Not only do 
these peptides enter cells, but they are able to bring a cargo such as nucleic acids, 
polymers, liposomes, nanoparticles, and small molecule drugs.[112]  
 In addition to L-arginine homopolymers, there are a variety of cell penetrating 
peptides exhibiting unique sequences and designs.  CPP’s are usually composed of 
less than 40 amino acids, but the sequences can vary greatly.    One way of improving 
CPP’s is to modify them by creating cyclic peptides,[113] dendrimers,[114] and helices.[115]  
However, most CPP’s are not selective and will enter any cell, which is why there is a 
demand for specificity in CPP design.  For example, CPP’s with tumor-homing 
capabilities have been designed by attaching a peptide known to accumulate in breast 
cancer tissue to a well-studied CPP.[116]  Almost all CPP’s have a multitude of positively 
charged residues, such as arginine. 
 Many cell penetrating peptides rely on positively charged residues to facilitate 
cell permeability.[117]  The reason for this is that the initial interaction between positively 
charged CPP’s and phospholipids in the plasma membrane is electrostatic.[118]  The 
positively-charged residues  interact with negatively charged polysaccharides such as 
heparin sulfate.   Furthermore, it has been shown that lysine is not as effective for 
cellular internalization as arginine.[111]  Therefore, it is evident that internalization not 
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only comes from positive charges, but from the guanadine moiety of the arginine 
residue. 
 We hypothesized that an arginine analog, L-canavanine, may be a good 
substitute for the residues of a CPP.  L-canavanine, an L-arginine analog, exhibits a 
side-chain residue with a lower pKa than its canonical counterpart.  Synthesizing an L-
canavanine homopolymer will allow for a poly-cationic peptide to form in a low pH 
environment, thus becoming cell permeable (Figure 4.2). 
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Figure 4.1: Structural differences between L-cav (left) and L-arg (right) highlighted in 
red. 
 
 
 
Figure 4.2: L-canavanine polypeptide becomes charged and permeable in the acidic 
extracellular environment of cancer cells. 
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4.2 L-Canavanine and Targeting Cancer 
 L-Canavanine, an L-arginine analog (Figure 4.1) exhibits a pKa of 7.04, which is 
significantly lower than the pKa of arginine (12.48).[119]    A general average over a 
variety of cancer types shows a pH of 6.84 in the extracellular environment.[120]  Regular 
physiological pH in the extracellular environment is generally ~7.4.  The matched pH of 
the extracellular environment of tumors and the pKa of canavanine may introduce a way 
to selectively charge a peptide in the vicinity of tumors in turn enabling permeability. 
 
4.3 Designing Poly-Canavanine Peptides 
 Peptides will be synthesized by a CEM Liberty microwave assisted peptide 
synthesizer.  The optimal arginine peptide for cell permeability is the nonaarginine 
peptide (R9).
[117]  Therefore, we hypothesize that nonacanavanine (Cav9) should be the 
starting place for our experiments.  It is known that pKa is transient in proteins and to 
correct for that we will vary our peptides by adding L-arginine residues in increasing 
quantities and positions (Table 4.1).[121] 
 
 
 
 
Table 4.1.  Peptides and controls with 5-Fam at N-terminus  
Arg9 5-FAM-RRRRRRRRR 
Peptide 1 5-FAM-RRRRXXXXX 
Peptide 2 5-FAM-XXXXXRRRR 
Peptide 3 5-FAM-XRXRXRXRX 
Cav9 5-FAM-XXXXXXXXX 
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4.4 Attempted syntheses of Fmoc-Cav-Pbf-OH. 
 4.4.1 Route 1 
 L-canavanine is an L-arginine analog.  Therefore, we decided to apply the same 
protecting group chemistry to L-canvanine as we used with L-arginine.  The reason for 
protecting the side-chain of L-arginine is because lactam formation resulting from 
nucleophilic attack of the side chain on the carboxylic acid during peptide synthesis is 
known to occur.[122]  During the attempted synthesis of Fmoc-Cav-Pbf, several synthetic 
routes were attempted.  Initially, the straightforward route was followed (Scheme 4.1).  
In this route L-canavanine was reacted with N-(9-
Fluorenylmethoxycarbonyloxy)succinimide (Fmoc-OSu) to afford the Fmoc-Cav-OH 
precursor in 69% yield.  However, multiple attempts to attach the Pbf group failed to 
give the desired product.  We believe that the oxyguanidine moiety on the residue of 
canavanine lacked the nucleophilicity to react with the sulfonyl chloride of Pbf-Cl.  The 
reaction mixture showed as a streak of multiple spots on TLC which is assumed to 
coincide with instability of the Fmoc protecting group. 
  
  
 
 
98 
 
Route 1 
  
 
 
 
 
 
 
 
 
 
 
Scheme 4.1.  Route 1 shows the first attempted synthesis of Fmoc-Cav-Pbf.  
Attachment of the Pbf protecting group was unsuccessful.   
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4.4.2 Route 2 
 We then sought to first protect the alpha-amine of L-canavanine with an 
orthogonal protecting group so that we could run the Pbf protection reaction in more 
basic conditions.  We decided to use N-[2-(Trimethylsilyl)ethoxycarbonyloxy]succinimide 
(Teoc-OSu), a protecting group to be later cleaved with fluorine anion, to protect the 
alpha-amine of L-canavanine (Scheme 4.2).  The next step was to protect the guanidine 
side-chain of L-canavanine with Pbf in the presence of NaOH.  Following Pbf protection 
then we planned to deprotect the alpha amine and re-protect it with Fmoc to make it 
suitable for peptide synthesis.  However, even under strongly basic conditions, the Pbf 
reaction continued to fail, even in the presence of a strong base.  No change in starting 
material was observed. 
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Route 2. 
 
 
Scheme 4.2.  Proposed synthesis of Fmoc-Cav-Pbf-OH through the use of an 
orthogonal protecting group for attachment of Pbf under more basic conditions. 
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4.4.3 Route 3 
 Although Pbf-protection of L-arginine is the preferred protection method, we 
hypothesized that we may be able to achieve peptide synthesis utilizing a different 
protecting group.  We decided to move forward with a tert-butyloxycarbonyl (Boc) 
protecting group.  This method does not work for arginine normally because of 
conversion to L-ornithine during solid phase peptide synthesis.[123]  It was suspected 
that L-canavanine would be inert to this reaction.  Initially, protection of Fmoc-Cav-OH 
with Boc-anhydride was unsuccessful (Scheme 4.3).   
We then decided to try to synthesize Fmoc-Cav-(Boc)2-OH in a series of smaller 
steps.  The thought was that we could use an Fmoc-protected 2-amino-4-bromobutyric 
acid (Scheme 4.4), which would undergo nucleophilic attack from a Boc-protected 
hydroxylguandine.  However, upon Fmoc-protection of the alpha-amine, irreversible 
lactone formation occurred.  We attempted to open the ring with HBr in MeOH, but were 
unsuccessful.   
 From this point we found it necessary to protect the carboxylic acid of 2-amino-4-
bromobutyric acid by synthesizing the methyl ester, followed by Fmoc protection and 
subsequent reaction with the Boc-protected hydroxylguanidine (Scheme 4.5).  We were 
successful up to the point of connecting the Boc-protected hydroxylguanidine.  Because 
of a lack of reaction as indicated by TLC, we hypothesized that the hydroxyl guanidine 
may be too sterically hindered to react.   Certainly we could push this reaction with basic 
conditions, but sensitivity of the Fmoc prevented this approach. 
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Route 3 
 
 
 
 
 
Scheme 4.3.  Synthesis of Fmoc-Cav-(Boc)2-OH utilizing Boc anhydride 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4.4.  Synthesis of Fmoc-Cav-(Boc)2-OH using the Boc protected 
hydroxylguanidine. 
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Route 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4.5.  Synthesis of Fmoc-Cav-(Boc)2-OH using the Boc protected 
hydroxylguanidine.  Initially, lactone formation is prevented by creating the methylester. 
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4.4 Discussion 
 Unfortunately, time restraints and failed synthetic progress have prevented this 
project from becoming fully realized.  After considering the need for side-chain 
protection during the synthesis of Arginine peptides, we decided that the same 
necessity may not be present for the unreactive residue of Canavanine.  We could try a 
synthesis of a Canavanine containing peptide without Pbf protection.  In the future, we 
hypothesize that it may be possible to use an oxyguanidine moiety that is not 
necessarily a canavanine derivative.  Guanidine-containing amino acids have been 
used before to mimic cell penetrating peptide and the same principles could be applied 
to oxyguanidine.[124] 
 
4.5 Experimental Section 
 All reagents and solvents were purchased from Sigma-Aldrich, VWR, or Fisher 
Scientific.   1H NMR spectra and 13C spectra were recorded at room temperature on 
a Bruker 400 MHz Ultrashield Plus.  Proton and Carbon chemical shifts are expressed 
in parts per million (ppm, δ scale) and are referenced to the solvent peak (DMSO) or 
TMS (CDCl3). 
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4.6 Chemical Synthesis 
 
 
 
Fmoc-Canavanine-OH, 4.1.  L-canavanine sulfate (250mg, 0.91mmol) was dissolved in 
H2O (500 μL) in the presence of TEA (191μL, 1.36mmol).  The solution was allowed to 
stir for 10 min.  To the solution was added, dropwise, Fmoc-OSu (277mg, 0.82mmol) in 
Acetone (500 uL).  TEA (10 μL aliquots) was added to keep the reaction at a pH of 8-
8.5.  A white precipitate formed and was collected and washed with H2O (3 x 1 mL) to 
yield 244mg (67%) of a white solid. 1H NMR is in agreement with previous reports.[125] 
 
1H NMR (400 MHz, Chloroform-d) δ 7.89 (d, J = 7.6 Hz, 2H), 7.72 (dd, J = 7.3, 3.4 Hz, 
2H), 7.44 – 7.38 (m, 2H), 7.33 (td, J = 7.5, 1.2 Hz, 2H), 4.24 (d, J = 5.3 Hz, 2H), 3.94 (d, 
J = 5.8 Hz, 0H), 3.74 (s, 1H), 2.10 – 1.95 (m, 1H), 1.95 – 1.76 (m, 1H). 
 
 
  
 
 
106 
 
 
 
Failed synthesis of Fmoc-Cav-(Pbf)-OH, 4.2.    Compound 4.1 (22.2mg, 55.7μM) was 
dissolved in a 1:1 mixture of Acetone:H2O (600 μL).  The mixture was stirred in an ice 
bath and TEA (14.6μL, 0.11mmol) was added.  The solution was allowed to stir for 10 
min.  Pbf-Cl (32.2mg, 0.11mmol), dissolved in acetone, was added via syringe pump 
over 30 minutes.  The pH was monitored and kept at ~8-8.5 by the addition of TEA.  
Once the addition of Pbf-Cl was complete, the reaction was allowed to warm to room 
temperature and react for an additional 2 h.  Disappearance of Pbf-Cl was monitored by 
TLC (20% MeOH:DCM).  Several new spots had formed and after separation by 
preparative TLC no desired product was isolated.  
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Failed synthesis of Fmoc-Cav-(Boc)2-OH, 4.3.  Compound 4.1 (37.4mg, 93.9μM) was 
dissolved in 10% Na2CO3 (350 μL) and stirred.  Boc anhydride (27.3mg, 0.19mmol) in 
dioxane (350 μL) was added in one portion.  The reaction was monitored for 
disappearance of starting material.  After 3 h the starting material was still present by 
TLC and the reaction was allowed to go overnight.  No disappearance of starting 
material was seen.  However, a new spot on TLC was observed and collected via flash 
column.  This new compound did not correspond to the product, and considerable  
starting material remained in the reaction.  
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Fmoc-(2-oxotetrahydrofuran-3-yl)carbamate, 4.4.  2-amino-4-bromobutyric acid (100 
mg, 0.38 mmol) was dissolved in H2O (2.4 mL) and stirred.  TEA (53 μL, 0.37 mmol) 
was added to the solution.  The solution was allowed to stir for 10 min and placed in an 
ice bath.  To the reaction mixture was added Fmoc-OSu (142.5 mg, 0.42 mmol) 
dissolved in DMF (0. 8mL), dropwise via syringe pump.  After 2 h the reaction mixture 
was allowed to warm to room temperature and allowed to run overnight (12 h).  
Disappearance of Fmoc-OSu was monitored by TLC and a new spot was seen forming.  
The new spot was separated by flash column chromatography (1:1 / EtOAc:Hexanes) to 
yield 138mg (87%) of a beige solid.  1H NMR is in agreement with previous reports.[126] 
 
1H NMR (400 MHz, Chloroform-d) δ 7.77 (d, J = 7.5 Hz, 2H), 7.59 (d, J = 7.5 Hz, 2H), 
7.44 – 7.38 (m, 2H), 7.35 – 7.30 (m, 2H), 4.44 (s, 4H), 4.23 (t, J = 6.5 Hz, 1H), 2.82 (d, J 
= 12.9 Hz, 1H), 2.27 – 2.14 (m, 1H). 
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Failed synthesis of (S)-methyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-
bromobutanoate, 4.5.  This reaction was kept dry and all starting materials were 
lyophilized overnight before use.  2 mL HBr in MeOH  (5-10%) was added to compound 
4.4 (28.8mg, 68.9μmol) and stirred at room temperature until all the starting material 
had disappeared on TLC.  Five new spots were observed on TLC and were separated 
by flash column (1:1 / EtOAc:Hexanes).  All fractions were undecipherable on NMR.  
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(Z)-tert-butyl(((tert-butoxycarbonyl)imino)(N-hydroxyl)methyl)carbamate, 4.6.  
N,N’-Di-Boc-1H-pyrazole-1-carboxamidine (250mg, 0.81mmol) was dissolved DMF (6.4 
mL) and a solution of hydroxylamine in H2O (50% by wt, 45.6 μL, 0.82 mmol) in a 
dropwise fashion.  The disappearance of starting material was monitored by TLC and 
the new spot was collected by flash column chromatography (4:1 / EtOAc:Hexanes).  
Fractions were lyophilized to yield 189 mg (85%) of a white solid. 1H NMR is in 
agreement with previous reports.[127] 
 
1H NMR (400 MHz, Chloroform-d) δ 2.95 (s, 1H), 2.88 (d, J = 0.7 Hz, 1H), 2.17 (s, 1H), 
1.49 (d, J = 5.3 Hz, 18H). 
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(S)-methyl 2-amino-4-bromobutanoate, 4.7.  2-amino-4-bromobutyric acid (51 mg, 
0.19 mmol) was placed in an oven dried vessel with a stir bar and place in an ice bath.  
Anhydrous methanol (1 mL) was added and stirred.  Thionyl chloride (28.1 μL, 0.39 
mmol) was then added slowly and dropwise.  The reaction was allowed to warm to room 
temperature, rotary evaporated, and a new spot on TLC (1:9 / MeOH:DCM) was 
collected by flash column chromatography to yield 18.3 mg (34%) of a beige solid.  1H 
NMR is in agreement with previous reports.[128] 
 
1H NMR (400 MHz, Chloroform-d) δ 4.40 (s, 3H), 3.95 (dd, J = 8.1, 5.2 Hz, 1H), 3.80 
(s, 3H), 3.69 – 3.56 (m, 2H), 2.49 – 2.37 (m, 1H), 2.29 (ddt, J = 14.4, 8.1, 6.1 Hz, 1H). 
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(S)-methyl-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-bromobutanoate, 4.8.  
Compound 4.7 (50mg, 0.18mmol) was dissolved in 606 μL (1:1 / dioxane:H2O).  DIPEA 
(32μL, 0.18mmol) was added and the solution was placed in an ice bath.  To the stirring 
reaction mixture was added Fmoc-Cl (46.7mg, 0.18mmol) in dioxane (500 μL), 
dropwise.  TLC was used to monitor disappearance of Fmoc-Cl and the reaction was 
complete after 2 h at which time the reaction mixture was rotovaporized and redissolved 
in a small amount of hexanes.  Product was separated by flash column chromatography 
(4:1 / Hexanes:EtOAc) to yield 44.5mg (59%) of a beige solid. 
 
1H NMR (400 MHz, Chloroform-d) δ 7.80 – 7.72 (m, 3H), 7.63 – 7.56 (m, 3H), 7.44 – 
7.36 (m, 3H), 7.34 – 7.28 (m, 3H), 5.41 (d, J = 8.3 Hz, 1H), 4.54 – 4.40 (m, 3H), 4.21 (t, 
J = 6.7 Hz, 1H), 3.76 (s, 3H), 3.38 (t, J = 7.0 Hz, 2H), 2.43 (ddd, J = 14.6, 10.0, 6.2 Hz, 
1H), 2.23 (dq, J = 14.5, 7.2 Hz, 1H). 
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Failed synthesis of Fmoc-Cav-(Boc)2-OMe, 4.9.   Compound 4.8 (44.5mg, 0.11mmol) 
was dissolved in DMF (0.9 mL) and stirred in the presence of NaI (1.6mg, 1.01μmol).  
Compound 4.6 (20mg, 0.11mmol) was dissolved in DMF (0.5 mL) and added to the 
reaction mixture in a dropwise fashion.  After two days no change in starting materials 
was observed on TLC.  
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Teoc-Cav-OH, 4.10.  L-canavanine sulfate (100mg, 0.36mmol) was dissolved in H2O (1 
mL).  TEA (102μL, 0.73mmol) was added and the solution was allowed to stir for 10 
min.  Teoc-OSu (105mg, 0.40mmol) was added in dioxane (1 mL).  The reaction was 
allowed to stir overnight (12 h).  A white precipitate formed and was collected by 
vacuum filtration.  The solid was washed with dioxane/H2O (1:1 / 3 x 5 mL) and placed 
on high vacuum overnight to yield 103 mg (88%) of a white solid. 
 
1H NMR (400 MHz, DMSO-d6) δ 6.79 (d, J = 7.2 Hz, 1H), 4.43 – 4.37 (m, 1H), 4.02 (t, J 
= 8.4 Hz, 2H), 2.05 – 1.75 (m, 2H), 0.94 – 0.88 (m, 2H), 0.02 (s, 9H). 
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Failed synthesis of Teoc-Cav-Pbf-OH, 4.11.  Compound 4.10 (27mg, 84.3μmol) was 
dissolved in 1mL (1:1 / H2O:Acetone) and placed on stir.  4M NaOH (100 μL) was 
added to the reaction mixture.  Pbf-Cl (27mg, 93.5μmol) was added in one portion to the 
stirring mixture.  A white precipitate formed, but was confirmed by NMR to be 
hydrolyzed Pbf starting material.  No new spots were witnessed on TLC. 
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Chapter 5: Conclusion 
 
 Drug discovery and chemotherapy for cancer has had its ups and downs over the 
centuries.  The main problem lies with the lack of specificity of chemotherapeutics and 
their propensity toward off-target toxicity.  Therefore, it is not only important to find new 
drugs with enhanced specificity for cancer cells over normal cells, but importantly, to 
discover ways to take proven chemotherapeutics and increase their specificity.  The 
latter is the focus of the Hartman Lab and I have focused this approach in to three 
distinct projects.  
 The first project, which dominated my research and ultimately proved the most 
fruitful in positive results, was turning combretastatin A4 into a photo activated drug.  
We were successful in showing that Azo-CA4 was not only a more potent inhibitor of 
tubulin polymerization in the light, but a more effective growth inhibitor in cancer cells in 
the light than in the dark.  Importantly, we showed that Azo-CA4 lost potency when 
removed from the light, demonstrating its photoswitchable activity.  It is important to 
continue shining light to sustain the activity of Azo-CA4. 
 The next two projects I worked on were very similar.  These projects used a 
photocleavable appendage to attach Doxorubicin to either a cell targeting ligand or to a 
cell impermeable molecule.  In the former project, Doxorubicin was linked to a folic acid 
through a nitroveratryl linker.  This molecule allowed us to be specific for cancer cells in 
two ways: 1) by the affinity of folic acid for overexpressed folate receptor in many 
cancer cell lines an 2) the use of an external radiation source to cleave doxorubicin from 
the ligand.  The important part of this project was to carefully construct this drug 
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conjugate so that we knew with complete certainty that the gamma-carboylic acid of 
folic acid was responsible for conjugation to the photocleavable linker.  The latter project 
involved optimizing and scaling up the synthesis of EDANS-DOX.  I began the synthesis 
of this molecule to test on mouse xenografts with the overall goal of improving the yield 
and synthetic methodology. 
The final project that I worked on was similar to the first three in that we sought to 
take known chemotherapeutics and increase specificity.  However, the project with poly- 
canavanine peptides did not utilize light to increase specificity.  Instead, we focused on 
the unique oxy-guanadine side chain of canavanine to try to create a peptide with cell 
permeability optimized for low pH environments.  Although, we did not get to construct a 
peptide with canavanine, the project presents a clearly promising project for future work. 
Overall, the work achieved throughout the course of my graduate career will have 
a strong, positive impact on the field of cancer-specific chemotherapeutics.  Through the 
continuance of my research we will further the fight against cancer and enhance the 
efficacy of existing drugs. 
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Appendix A: NMR Data 
1H NMR of 3-((tert-butyldimethylsilyl)oxy)-4-methoxynitrobenzene, 2.1. 
 
 
 
 
 
 
 
 
 
119 
 
13C NMR of 3-((tert-butyldimethylsilyl)oxy)-4-methoxynitrobenzene, 2.1. 
 
 
 
 
 
 
 
 
 
  
 
 
120 
 
1H NMR of 3-((tert-butyldimethylsilyl)oxy)-4-methoxyaniline, 2.2. 
 
 
 
 
 
 
 
  
 
 
121 
 
13C NMR of 3-((tert-butyldimethylsilyl)oxy)-4-methoxyaniline, 2.2. 
 
 
 
 
 
 
 
 
 
  
 
 
122 
 
1H NMR of (E)-1-(3-((tert-butyldimethylsilyl)oxy)-4-methoxyphenol)-2-(3,4,5-
trimethoxyphenyl)diazene, 2.3. 
 
 
 
 
 
  
 
 
123 
 
13C NMR of (E)-1-(3-((tert-butyldimethylsilyl)oxy)-4-methoxyphenol)-2-(3,4,5-
trimethoxyphenyl)diazene, 2.3. 
 
 
 
 
 
 
 
 
  
 
 
124 
 
1H NMR of (E)-2-methoxy-5-((3,4,5-trimethoxyphenyl)diazenyl)phenol, 2.4. 
 
 
 
 
 
 
  
 
 
125 
 
13C NMR of (E)-2-methoxy-5-((3,4,5-trimethoxyphenyl)diazenyl)phenol, 2.4. 
 
  
 
 
126 
 
1H NMR of Bis-p-tosyltriethylene glycol, 3.1 
 
 
 
  
 
 
127 
 
1H NMR of bis-azidetriethylene glycol, 3.2 
 
 
 
  
 
 
128 
 
1H NMR of 2-(2-(2-azidoethoxy)ethoxy)ethanamine, 3.3. 
 
 
 
  
 
 
129 
 
19F NMR of N 2,10-Bis(trifluoroacetyl)pyrofolic acid/anhydride, 3.4. 
 
 
 
 
  
 
 
130 
 
1H NMR of N10-(Trifluoroacetyl)pyrofolic acid, 3.5. 
 
 
 
 
  
 
 
131 
 
1H NMR of Pteroyl hydrazide, 3.6.  
 
 
 
  
 
 
132 
 
1H NMR of Pteroyl azide, 3.7. 
 
 
 
 
 
 
 
 
133 
 
1H NMR of Boc-Glu-OtBu-NHS, 3.8. 
 
 
 
  
 
 
134 
 
1H NMR of Boc-Glu-OtBu-PEG-Azide, 3.9. 
 
 
 
 
  
 
 
135 
 
13C NMR of Boc-Glu-OtBu-PEG-Azide, 3.9. 
  
 
 
136 
 
1H NMR of Glu-PEG-Azide, 3.10 
 
 
 
   
 
 
137 
 
1H NMR of 2,5-dioxopyrrolidin-1-yl 4-(4-(1-hydroxyethyl)-2-methoxy-5-
nitrophenoxy)butanoate, 3.12.  
  
 
  
 
 
138 
 
1H NMR of 4-(4-(1-hydroxyethyl)-2-methoxy-5-nitrophenoxy)-N-(prop-2-yn-1-
yl)butanamide, 3.13. 
 
 
  
 
 
139 
 
 
1H NMR of 1-(5-methoxy-2-nitro-4-(4-oxo-4-(prop-2-yn-1-
ylamino)butoxy)phenyl)ethyl (4- nitrophenyl) carbonate, 3.14 
 
  
  
 
 
140 
 
1H NMR of Dox-NV-alkyne, 3.15. 
 
 
  
 
 
141 
 
1H NMR of 2,5-dioxopyrrolidin-1-yl 4-azidobenzoate, 3.16. 
 
 
  
 
 
142 
 
1H NMR of 5-((2-(4-azidobenzamido)ethyl)amino)naphthalene-1-sulfonic acid, 3.17. 
 
 
  
 
 
143 
 
1H NMR of Dox-NV-EDANS, 3.18. 
 
 
 
  
 
 
144 
 
1H NMR of Fmoc-Cav-OH, 4.1. 
 
 
  
 
 
145 
 
1H NMR of Fmoc-(2-oxotetrahydrofuran-3-yl)carbamate, 4.4. 
 
 
 
 
  
 
 
146 
 
1H NMR of (Z)-tert-butyl(((tert-butoxycarbonyl)imino)(N-
hydroxyl)methyl)carbamate, 4.6. 
 
 
 
 
  
 
 
147 
 
1H NMR of (S)-methyl 2-amino-4-bromobutanoate, 4.7. 
 
 
 
 
  
 
 
148 
 
1H NMR of (S)-methyl-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-
bromobutanoate, 4.8. 
 
 
 
 
  
 
 
149 
 
1H NMR Teoc-Cav-OH, 4.10. 
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